
Non-surgical Therapies for Early-stage Non-small Cell Lung Cancer

June 2023

VA



U.S. Department of Veterans Affairs

Veterans Health Administration
Health Services Research & Development Service

Recommended citation: Sultan S, Ullman K, Ester E, et al. Non-surgical Therapies for Early-stage Non-small Cell Lung Cancer: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2023.

AUTHORS

Author roles, affiliations, and contributions to the present report (using the [CRediT taxonomy](#)) are summarized in the table below.

Author	Role and Affiliation	Report Contribution
Shahnaz Sultan, MD, MSC	Project Lead, Core Investigator, Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis VA Health Care System Minneapolis, MN Professor of Medicine, Division of Gastroenterology, Hepatology & Nutrition, University of Minnesota Minneapolis, MN	Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing, Supervision, Project administration
Kristen Ullman, MPH	Program Manager, Minneapolis Evidence Synthesis Program (ESP) Center Minneapolis, MN	Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing
Elizabeth Ester, MD	Staff Physician, Minneapolis VA Health Care System Adjunct Assistant Professor, Department of Radiation Oncology, University of Minnesota Minneapolis, MN	Conceptualization, Methodology, Writing – review & editing
Anne Melzer, MD, MS	Staff Physician, Minneapolis VA Health Care System Assistant Professor, Division of Pulmonary and Critical Care, University of Minnesota Minneapolis, MN	Conceptualization, Methodology, Writing – review & editing
Maylen Anthony, MPH	Project Coordinator, Minneapolis ESP Center Minneapolis, MN	Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing, Project administration
Rosemary F. Kelly, MD	Staff Physician, Minneapolis VA Health Care System Professor, Department of Surgery, University of Minnesota Minneapolis, MN	Conceptualization, Methodology, Writing – review & editing
Adrienne Landsteiner, PhD	Senior Scientist, Minneapolis ESP Center Minneapolis, MN	Conceptualization, Methodology, Writing – review & editing
Christopher Stampe, MD	Vascular & Interventional Radiology, Minneapolis VA Health Care System	Writing – review & editing

Author	Role and Affiliation	Report Contribution
Jeffrey Thiboutot, MD, MHS	Assistant Professor of Medicine, Johns Hopkins University Baltimore, MD	Writing – review & editing
Timothy J. Wilt, MD, MPH	Director, Minneapolis ESP Center Minneapolis, MN	Conceptualization, Methodology, Investigation, Writing – review & editing, Supervision

This report was prepared by the Evidence Synthesis Program Center located at the **Minneapolis VA Health Care System**, directed by Timothy J. Wilt, MD, MPH and Wei Duan-Porter, MD, PhD and funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development.

The findings and conclusions in this document are those of the author(s) who are responsible for its contents and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

PREFACE

The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted health care topics of importance to clinicians, managers, and policymakers as they work to improve the health and health care of Veterans. These reports help:

- Develop clinical policies informed by evidence;
- Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- Set the direction for future research to address gaps in clinical knowledge.

The program comprises four ESP Centers across the US and a Coordinating Center located in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Center Program. The Coordinating Center was created to manage program operations, ensure methodological consistency and quality of products, interface with stakeholders, and address urgent evidence needs. To ensure responsiveness to the needs of decision-makers, the program is governed by a Steering Committee composed of health system leadership and researchers. The program solicits nominations for review topics several times a year via the [program website](#).

The present report was developed in response to a request from the National Radiation Oncology Program for an evidence review on optimal treatment for stage I lung cancer. The scope was further developed with input from Operational Partners (below), the ESP Coordinating Center, the review team, and the technical expert panel (TEP). The ESP consulted several technical and content experts in designing the research questions and review methodology. In seeking broad expertise and perspectives, divergent and conflicting opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Ultimately, however, research questions, design, methodologic approaches, and/or conclusions of the review may not necessarily represent the views of individual technical and content experts.

ACKNOWLEDGMENTS

The authors are grateful to the following individuals for their contributions to this project:

Operational Partners

Operational partners are system-level stakeholders who help ensure relevance of the review topic to the VA, contribute to the development of and approve final project scope and timeframe for completion, provide feedback on the draft report, and provide consultation on strategies for dissemination of the report to the field and relevant groups.

Drew Moghanaki, MD, MPH

Staff Physician

Co-Director Lung Precision Oncology Program

VA Greater Los Angeles Healthcare System

Technical Expert Panel

To ensure robust, scientifically relevant work, the TEP guides topic refinement; provides input on key questions and eligibility criteria, advising on substantive issues or possibly overlooked areas of research; assures VA relevance; and provides feedback on work in progress. TEP members are listed below:

Jed Gorden, MD

Pulmonary Critical Care, Thoracic Surgery, Thoracic Surgical Oncology
Swedish Medical Group, Seattle

Lorraine Cornwell, MD, FACS

Section Chief of Cardiothoracic Surgery
Michael E. DeBakey VA Medical Center, Houston

Russell Hales, MD

Department of Radiation Oncology & Molecular Radiation Sciences
Johns Hopkins University

Christopher Slatore, MD, MS

Chief Consultant, VHA National Center for Lung Cancer Screening
Director, VISN 20 Centralized Lung Cancer Screening Program
Portland VA Healthcare System

Robert Suh, MD

Interventional Radiology, Diagnostic Radiology
UCLA

Peer Reviewers

The Coordinating Center sought input from external peer reviewers to review the draft report and provide feedback on the objectives, scope, methods used, perception of bias, and omitted evidence (see Appendix D for disposition of comments). Peer reviewers must disclose any relevant financial or non-financial conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The Coordinating Center works to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

TABLE OF CONTENTS

Authors.....	i
Preface.....	iii
Acknowledgments.....	iii
Abbreviations Table.....	vii
Executive Summary.....	1
Introduction.....	8
Methods.....	9
Topic Development.....	9
Key Questions.....	9
Protocol.....	10
Data Sources and Searches.....	10
Study Selection.....	10
Data Abstraction and Assessment.....	11
Synthesis.....	12
Results.....	13
Key Questions 1 and 2.....	13
Key Question 3.....	23
Discussion.....	31
Key Messages.....	31
Limitations.....	34
Applicability.....	34
Future Research.....	35
Conclusions.....	35
References.....	37
Appendix A. Search Strategies.....	41
Appendix B. Excluded Studies.....	44
Appendix C. Risk of Bias Ratings (KQ1 Only).....	54
Appendix D. Peer Review Disposition.....	55

FIGURES AND TABLES

Table 1. Eligibility Criteria.....	10
Figure 1. KQs 1 and 2 Literature Flowchart.....	14

Table 2. Overview of STARS (Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer) and ROSEL (Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer) Clinical Trial Information	15
Table 3. Study Characteristics for All Eligible Trials Reporting Survival or Adverse Events	19
Table 4. Certainty of Evidence for SABR/SBRT versus Surgery for Lung Cancer Outcomes....	21
Table 5. Study Characteristics for All Eligible Publications Reporting Quality of Life	22
Figure 2. KQ3 Literature Flowchart	25
Table 6. Detailed Characteristics for Eligible Publications for Key Question 3	26
Figure 3. Outcomes Reported by Comparisons	27
Figure 4. Evidence Map of Publications Reporting Ablation versus Radiotherapy or Ablation versus Surgery.....	28
Table 7. Outcomes Reported by Eligible Publications for Key Question 3	29
Table 8. Specific Adverse Events Reported by Eligible Publications for Key Question 3	30

ABBREVIATIONS TABLE

Abbreviation	
AHRQ	Agency for Healthcare Research and Quality
AJCC	American Joint Commission on Cancer
ARD	Adjusted risk difference
BAC	Bronchioloalveolar carcinoma
BED	Biologically effective dose
CBO	Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing (Dutch Institute for Healthcare Improvement)
CI	Confidence interval
CT	Computed tomography
CVA	Cerebral vascular accident
ECOG	Eastern Cooperative Oncology Group
EORTC QLQ-C30	The 30-item European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire
EQ-5D	The EuroQoL disease-specific questionnaire
ESP	Evidence Synthesis Program
FEV	Fluorodeoxyglucose-positron emission tomography
GDT	Guideline Development Tool
GRADE	Grading of Recommendation, Assessment, Development, and Evaluation
Gy	Gray
HR	Hazard ratio
IASCL	International Association for the Study of Lung Cancer
IQR	Interquartile range
KQ	Key question
L	Left
LC-13	The 13-item lung cancer supplement to the EORTC QLQ-C30
MI	Myocardial infarction
MWA	Microwave ablation
NA	Not available
NCDB	National Cancer Database
NR	Not reported
NSCLC	Non-small cell lung cancer
PET	Positron emission tomography
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROSPERO	International Prospective Register of Systematic Reviews
QoL	Quality of life
R	Right
RCT	Randomized controlled trial
RFA	Radiofrequency ablation
RoB	Risk of bias

Abbreviation	
ROSEL	Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer
RR	Risk ratio
SABR	Stereotactic ablative radiotherapy
SBRT	Stereotactic body radiation therapy
SD	Standard deviation
SEER	Surveillance, Epidemiology and End-Results database
STARS	Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-Small Cell Lung Cancer
TEP	Technical expert panel
TNM	Tumor, node,metastasis
US/USA	United States of America
USPSTF	US Preventative Services Task Force
VA	Veterans Health Administration
VALOR	Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy trial
VATB	Video-assisted thoracotomy biopsy
VATL	Video-assisted thoracotomy lobectomy
VATS	Video-assisted thorascopic surgery
VATS L-MLND	Video-assisted thorascopic surgical lobectomy with mediastinal lymph node dissection

EXECUTIVE SUMMARY

Key Findings

Key Questions 1 and 2

- KQ1: Among adults with medically operable stage I non-small cell lung cancer, what are the benefits and harms of SBRT compared to surgery? KQ2: Do benefits and harms of SBRT/SABR compared to surgery differ by patient characteristics (*eg*, age, comorbidities, performance status), tumor characteristics (size, location, stage), surgery characteristics (type of surgery [minimally invasive vs open], type of resection [lobectomy, wedge resection, segmental resection, sleeve resection]), or SBRT characteristics (*eg*, dose, fractionation)?
- Based on pooled data from the STARS and ROSEL trials comparing SABR/SBRT versus surgery, the evidence for 3-year survival, 3-year recurrence-free survival, quality of life, and adverse events is very uncertain (very low COE).
 - Only 2 randomized trials, STARS and ROSEL, were identified that evaluated the role of SABR/SBRT compared to surgery for patients with medically operable stage I non-small cell lung cancer; both were terminated early due to lack of enrollment.
- No randomized trials were identified that examined if the benefits and harms of SABR/SBRT differ by patient characteristics, tumor characteristics, surgery characteristics, type of resection, or SBRT characteristics.
- There is an urgent need for randomized controlled trials to examine the comparative effectiveness of SABR/SBRT versus surgery for patients with medically operable stage I lung cancer.

Key Question 3

- KQ3: What are the quantity and characteristics of evidence assessing the comparative effects of ablative therapies as monotherapy or combined with other ablative therapies versus surgical, radiotherapy, or ablative therapies for patients with early stage I non-small cell lung cancer, by type of intervention, patient/tumor characteristics, study design, and outcomes?
- No RCTs examined ablation therapies for stage 1 lung cancer. The following ablation therapies have been studied in non-randomized comparative studies: cryoablation, radiofrequency ablation, microwave ablation, and laser ablation. Radiofrequency ablation was the most commonly studied ablative therapy ($k = 11$).
- Six retrospective studies reported on ablation compared with SBRT/SABR:
 - Ablation (any type combined) versus SBRT/SABR ($k = 3$)
 - Radiofrequency ablation versus SBRT/SABR ($k = 3$)

- Ten retrospective studies reported on ablation compared with surgery:
 - Microwave ablation versus surgery ($k = 4$)
 - Radiofrequency ablation versus surgery ($k = 4$)
 - Ablation (any type combined) versus surgery ($k = 2$)
 - SBRT/SABR versus radiofrequency ablation versus surgery ($k = 2$)
- Two studies compared ablation with SBRT/SABR and surgery:
 - SBRT/SABR versus radiofrequency ablation versus surgery ($k = 2$)
- Most studies had 300 or fewer participants ($k = 12$) and were conducted in the US ($k = 9$), Europe ($k = 3$), China ($k = 3$), Japan ($k = 2$), and South Korea ($k = 1$) except for 6 studies of administrative datasets (NCDB and SEER) that included 2,000-30,000 participants.
- The majority of studies reported on the following outcomes: overall survival ($k = 18$), disease-free survival ($k = 8$), local/regional recurrence ($k = 12$), and any adverse events ($k = 11$). No studies reported on quality of life. None of these studies were conducted in Veterans and most studies were conducted prior to widespread lung cancer screening.

INTRODUCTION

Lung cancer is the leading cause of cancer-related deaths in the United States (US). The majority of lung cancers are diagnosed at advanced stages but with the advent of lung cancer screening, the number of individuals diagnosed with early-stage lung cancer has continued to rise. Within the Veterans Health Administration (VA), approximately 8,000 Veterans are diagnosed with and treated for lung cancer every year. Surgery, including lobectomy, segmentectomy, wedge resection, and sleeve resection with or without the use of minimally invasive approaches, has been considered the standard of care for individuals with early-stage lung cancer who are deemed to be medically operable. Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) are frequently offered to individuals considered to be medically inoperable for various reasons (due to advanced age or with comorbidities that place them at high risk for severe perioperative complications). Promising results with SBRT/SABR in patients deemed to be medically inoperable have led to studies evaluating the efficacy and long-term outcomes of this therapy as an alternative to surgery in medically operable patients. These results raise questions about definitive treatment options for early-stage lung cancer.

This review addresses important questions regarding the comparative effectiveness of surgery versus SBRT/SABR as well as the current body of evidence for ablative therapies such as radiofrequency ablation, cryoablation, microwave ablation, laser ablation, and brachytherapy in the management of medically operable stage I lung cancer. This topic was nominated by the National Radiation Oncology Program. Additionally, this review provides the background rationale for an ongoing VA Cooperative Study, a randomized trial of surgery versus SBRT (NCT02984761). Findings will be used to inform use of treatment modalities in patients with stage I lung cancer who are deemed medically operable.

The Key Questions (KQs) for this review are:

- KQ1: Among adults with medically operable stage I non-small cell lung cancer, what are the benefits and harms of SBRT compared to surgery?
- KQ2: Do benefits and harms of SBRT/SABR compared to surgery differ by patient characteristics (eg, age, comorbidities, performance status), tumor characteristics (size, location, stage), surgery characteristics (type of surgery [minimally invasive vs open], type of resection [lobectomy, wedge resection, segmental resection, sleeve resection]), or SBRT characteristics (eg, dose, fractionation)?
- KQ3: What are the quantity and characteristics of evidence assessing the comparative effects of ablative therapies as monotherapy or combined with other ablative therapies versus surgical, radiotherapy or ablative therapies for patients with early stage I non-small cell lung cancer, by type of intervention, patient/tumor characteristics, study design, and outcomes?

METHODS

Data Sources and Searches

Two search strategies were developed to address the KQs. We searched MEDLINE and Embase from inception to September 2022. We supplemented these searches with a review of relevant systematic review bibliographies. We limited the searches to published and indexed articles involving human subjects available in the English language.

Study Selection

Based on discussion with our nominating partner and technical expert panel members, we focused on randomized controlled trials for KQs 1 and 2 because prior work that relied on observational studies (even with the use of statistical techniques to adjust for confounding) was deemed inadequate to accurately inform comparative effectiveness and harms. As the goal for KQ3 was revised to include an evidence map of comparative studies of ablative therapies, our study eligibility criteria included randomized trials or observational studies with a comparator arm (KQ3) that evaluated ablation therapy compared with surgery (or SBRT/SABR) or other ablation therapies. Using prespecified inclusion/exclusion criteria, titles and abstracts were screened independently by at least 1 reviewer from the systematic review team for potential relevance. Any article excluded at the abstract level required confirmation by a second reviewer; articles included by either reviewer were advanced to the full-text review stage. At the full-text screening stage, 2 independent reviewers agreed on the final inclusion and exclusion decision. Disagreements were resolved by consensus among the review team. Articles that met eligibility criteria were included for data abstraction.

Data Abstraction and Assessment

Data from eligible studies were abstracted by 1 reviewer and verified by a second reviewer. Any disagreements were resolved by consensus between reviewers or arbitrated by the systematic review authors. For KQs 1 and 2, we abstracted the following information: trial characteristics (eg, inclusion/exclusion criteria), sample size, intervention and comparison characteristics, demographic information (eg, age, tumor stage), surgery characteristics, SBRT characteristics, and any information related to outcomes of interest. In addition to data from published articles, trial investigators were contacted and asked to provide data stratified by treatment arm (if

available) to supplement the published data. Two reviewers independently assessed risk of bias (RoB) using the Cochrane RoB 2 tool and resolved disagreements via discussion and consensus.

For KQ3, we abstracted the following information: sample size, interventions and comparisons, demographic information (*eg*, age), country, study design, surgery and ablation therapy characteristics, and outcomes reported. No formal risk of bias assessment was performed for studies meeting eligibility criteria.

Synthesis

For KQs 1 and 2, we identified publications that conducted a quantitative analysis of data from the 2 trials and used this to inform our review. We evaluated the overall certainty of evidence for overall survival, lung-cancer-specific survival, quality of life, and adverse events of grade 2 or higher, according to the GRADE approach. One author independently rated the certainty of evidence for each outcome, and any disagreement was resolved through group consensus with the team.

For KQ3, because of the heterogeneity of identified studies, no formal synthesis of study results was performed. To summarize the evidence on ablation therapies, we provided a descriptive overview of the data in a narrative review and provided visual graphics, including tables and a bubble plot, to summarize the key features of the studies. We mapped the results by intervention versus comparison, types of outcomes, and sources of data (*eg*, populations).

RESULTS

Results of Literature Search

For KQ1, our search identified 2,959 potentially relevant citations. After title and abstract screening, 27 were moved forward to full-text review. Of those 27, we identified only 2 publications which met inclusion criteria. Studies were excluded for the following reasons: ineligible publication type or study design (*eg*, commentaries or non-randomized studies), ineligible intervention or outcome (*eg*, radiotherapy vs chemotherapy or chemoradiation), and ineligible outcome (*eg*, treatment preferences). No eligible publications were identified that addressed KQ2.

For KQ3, of 3,095 potentially relevant citations after title and abstract screening, 131 were moved forward to full-text review. Of those 131, we identified 18 publications which met inclusion criteria.

Summary of Results for Key Questions

KQ1

One publication pooled data from 2 trials ($N = 58$): the Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-Small Cell Lung Cancer (STARS) trial and the Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer (ROSEL) trial. Both trials had similar inclusion criteria and were terminated early due to low recruitment. Both trials reported overall survival at 1 and 3 years, 3-year recurrence-free survival, and adverse events. The second publication reported quality of life data from the ROSEL trial ($N = 19$). Both publications were judged to have “some concerns” for risk of bias. Across outcomes, there is

insufficient evidence on the comparative effectiveness of SBRT/SABR versus surgery for overall survival at 3 years, recurrence-free survival at 3 years, grade ≥ 3 adverse events, and quality of life.

KQ3

Radiofrequency ablation was the most commonly studied ablative therapy. In general, across studies, ablation was compared with surgery or radiotherapy. The majority of publications were single-site retrospective cohort studies. Six publications used national US databases, including the National Cancer Database (NCDB) and the Surveillance, Epidemiology and End-Results Database (SEER). Most studies were small (range 22-289 patients) with the exception of the 6 large national database studies which included several thousand patients (range 2,000-30,000 patients). All the studies included older adults and most studies did not report on whether participants were formally assessed, at the time of treatment, as medically operable or inoperable. Two studies reported on only medically operable individuals. None of the studies were conducted in Veterans. While most studies provided some information about tumor characteristics, there was no consistency across studies on which characteristics were reported. There was variation in reporting of tumor size (mean, median, or range provided) and cancer stage. With respect to outcomes, all publications reported overall survival ($k = 18$), most reported on local or regional recurrence ($k = 12$) and adverse events ($k = 11$), while fewer reported on lung-cancer-specific survival ($k = 8$) or distant recurrence ($k = 7$).

DISCUSSION

Key Findings and Strength of Evidence

Our systematic review has several key findings and limitations. The main limitations and key findings are based on the sparseness and low overall certainty of existing evidence. We found insufficient evidence to inform the comparative effectiveness of SBRT/SABR versus surgery for stage I medically operable lung cancer. Based on 2 studies, we have very low certainty of the comparative effectiveness of SABR versus surgery for the following outcomes: 3-year survival, 3-year recurrence free survival, adverse events, and quality of life. Our very low certainty in the estimates is based on concerns of performance bias, detection bias, and indirectness with very small number of events in the 2 intervention groups (only 7 total deaths over 3 years) and low rates of minimally invasive surgical resection in the surgery arm. The 2 identified RCTs did not employ video-assisted or robotic surgical approaches and thus may not be representative of harms or quality of life from contemporary less invasive surgical approaches.

We found no data evaluating whether benefits and harms of SBRT compared with surgery differed by patient, tumor characteristics, surgery or SBRT characteristics. These characteristics are important as clinical decisions often include these factors, and variation in these characteristics may confound findings from observational studies.

The comparative effectiveness (and harms) of 2 treatments is ideally based on a randomized trial designed to minimize selection bias as well as performance and detection bias, which can lead to an inaccurate estimate of treatment effects. Several observational studies comparing patient outcomes with surgery versus SBRT have attempted to adjust for confounding by using statistical techniques. One study, outlined below, attempted to use a revised protocol of the STARS trial to re-accrue patients as a prospective single-center study cohort and used propensity

matching to adjust for prognostic baseline differences between the groups. Participants were compared to a cohort of individuals that underwent video-assisted thorascopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND) using a protocol-specified propensity matched comparison. The authors reported that overall survival at 3 years in the SABR group was 91% (95% CI [85%, 98%]) compared with 91% (95% CI [76%, 98%]) in the propensity-matched VATS-LMND cohort and overall survival at 5 years in the SABR cohort was 87% (95% CI [79%, 95%]) compared with 84% (95% CI [76%, 93%]) in the surgery cohort. Overall, 10 deaths occurred, and 15 patients developed progression in the SABR group over a median follow-up of 5.1 years. In the surgery group, there were 15 deaths and 6 recurrences or distant metastases. Based on these findings, the authors concluded that SABR was non-inferior to VATS-MLND for operable stage IA NSCLC. However, the authors acknowledged persistent concerns about selection bias due to lack of randomization and about determination of medical operability since the surgical cohort was not treated under a fixed protocol.

Based on our evidence map, we found no RCTS of ablative therapies for stage I lung cancer. We found only a limited number of comparative studies of ablative treatments versus surgery for lung cancer. All were observational and many were small single-center reports. While ablative therapies are widely used for palliative treatment in many cancer types, especially among individuals with metastatic disease, there are few reports of these therapies used as potentially definitive therapy in localized lung cancer. Most studies did not specify medically operable patients and did not provide the stage of disease. Because the heterogeneity of the studies with respect to patient populations, interventions, and study designs, we did not pool across studies and make inferences about effect size or overall certainty of evidence. Furthermore, studies commonly reported on ablation versus surgery or SBRT/SABR without providing data on specific ablative therapies. Large studies using administrative data are unlikely to capture information on medical operability. When individual studies of ablation were reported, the most common ablative therapy was radiofrequency ablation. The majority of studies reported on overall and lung-cancer-specific survival as well as disease recurrence with heterogenous reporting of treatment-related adverse events, and no data on quality of life. None of the studies provided information on patient, tumor, or treatment characteristics likely of importance for decision-making.

Applicability

Many of the reported studies were conducted prior to widespread lung cancer screening with low-dose CT scanning, which may result in detection of smaller lesions and concerns for overtreatment. None of the studies were specific to VA populations. The ongoing VALOR (Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy) RCT, funded by the VA Cooperative Studies Program (CSP #2005), aims to recruit 670 Veterans from at least 16 VA hospitals to compare stereotactic radiotherapy to standard lobectomy or segmentectomy for the treatment of medically operable, histologically confirmed, centrally or peripherally located stage I non-small cell lung cancers.

Future Research

The results of our systematic review underscore the recognition that data from randomized controlled trials, especially that of the VA VALOR Cooperative Study, are critically needed to inform decisions around primary treatment for stage I lung cancer. The scarcity of randomized trial data is a major limitation in understanding the comparative effectiveness of different

treatment strategies. This is particularly relevant given that the updated recommendations for expanded lung cancer screening incorporate surgical candidacy or willingness to undergo surgery as a prerequisite for offering screening. Future studies should:

- Use consistent terminology or definitions for medically operable disease using standardized protocols for enrollment to further minimize selection bias or confounding by indication and provider bias for enrollment.
- Ensure adequate experience and training in the performance of minimally invasive surgery and ablative therapies.
- Ensure adequate enrollment and follow-up to have adequate sample size to detect clinically meaningful differences in overall and cancer-specific survival, tumor-free progression, adverse effects, quality of life, and long-term side effects (using consistent definitions).
- Be pragmatic in design to ensure that studies address the range of patients, tumors, and interventions under clinical consideration for individuals with newly diagnosed lung cancer (especially screen detected).
- Recruit patient engagement groups to understand barriers and seek solutions to randomization in trials of these vastly different treatments, and examine values and preferences, acceptability, and feasibility.
- Assess potential expansion of treatment options for stage I lung cancer to include SABR/SBRT and/or ablative therapies (potentially as a 3-arm trial).
- Explore how inclusion of screen-detected lesions would influence screening and treatment decisions and resultant net benefits. This includes use of less invasive therapies for small, indolent lung cancers among older, sicker adults who would otherwise not have been candidates for screening or subsequent treatment.

Conclusions

In summary, we found insufficient evidence on the comparative effectiveness and harms of surgery versus SBRT/SABR for adults with medically operable stage I lung cancer. Furthermore, the field of ablative therapies continues to innovate and is becoming more widely studied. Because of treatment outcome uncertainty, the increased implementation of lung cancer screening programs, and the fact that lung cancer remains one of the most common and lethal cancers globally, there is a critical need for robust evidence on comparative treatment effects. Additionally, information is needed on patient preferences and values to inform the management of patients with medically operable stage I non-small cell lung cancer.

EVIDENCE REPORT

INTRODUCTION

Lung cancer is the leading cause of cancer-related deaths in the United States (US), with an estimated 238,340 new cases of lung cancers expected in 2023 and 127,070 estimated deaths.¹ The majority of lung cancers are diagnosed at advanced stages, but with the advent of lung cancer screening, the number of individuals diagnosed with early-stage lung cancer has continued to rise.² Within the Veterans Health Administration (VA),³ approximately 8,000 Veterans are diagnosed with and treated for lung cancer every year. Non-small cell lung cancer (NSCLC) represents approximately 80-85% of lung cancers and includes the following subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung cancer. With a median age at diagnosis of 70 years, many individuals diagnosed with NSCLC have comorbid conditions due to advanced age and longstanding tobacco use, which may influence the choice of treatment as well as impact patient-important outcomes.

Surgery has been considered the standard of care for individuals with early-stage lung cancer who are deemed medically operable.⁴ Surgical treatment includes lobectomy, segmentectomy, wedge resection, and sleeve resection with or without the use of minimally invasive approaches such as robotic or video-assisted thoracoscopic surgery (VATS). Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) are frequently offered to individuals considered to be medically inoperable for various reasons, including advanced age, inadequate pulmonary reserve, and multiple comorbidities that place them at high risk for severe perioperative complications. Promising results with SBRT/SABR in medically inoperable patients have led to studies evaluating the efficacy and long-term outcomes of SBRT/SABR in medically operable patients, thus raising questions about the optimal treatment approach for early-stage lung cancer.

This review addresses important questions regarding the comparative effectiveness and harms of surgery versus SBRT/SABR, as well as the role of ablative therapies such as radiofrequency ablation, cryoablation, microwave ablation, laser ablation, and brachytherapy in the management of medically operable stage I lung cancer. This is a priority for the VA considering the burden of lung cancer within the VA health care system and the increased number of diagnoses of stage I lung cancer with lung cancer screening. Furthermore, current US Preventive Services Task Force (USPSTF) recommendations for the decision to pursue lung cancer screening are contingent on an individual's ability or willingness to have curative lung surgery.⁵ The role of SBRT/SABR in the context of screening decisions or treatment options following a screen-detected or incidentally detected lung cancer is not well outlined but is very relevant to clinical practice and policy decisions. This topic, nominated by the National Radiation Oncology Program, reviews the evidence for the optimal treatment for stage I lung cancer and provides the background rationale for an ongoing VA Cooperative Study, a randomized trial of surgery versus SBRT that is currently enrolling participants.⁶ Findings from this review will be used to inform the evidence on the use of treatment modalities in patients with stage I lung cancer who are deemed medically operable.

METHODS

TOPIC DEVELOPMENT

In collaboration with our VA Operational Partners and a technical expert panel (TEP), we developed the key questions and refined the scope of this review. Specifically, while the original protocol focused on surgery compared with non-surgical modalities for patients with stage I lung cancer, the scope of the review was expanded to include an evidence map. The evidence map would outline the body of evidence for comparative studies of ablation therapies in lung cancer, acknowledging the rapidly expanding role for ablation therapy for this indication. Furthermore, comparative effectiveness (and harm) studies for 2 (or more) treatment regimens are best evaluated through randomized head-to-head comparisons, as the body of evidence for comparative effectiveness from observational studies is fraught with issues around confounding (selection bias, performance bias, detection bias) that cannot be fully accounted for using statistical techniques, such as propensity matching. In consultation with our stakeholders and to meet the needs of the National Radiation Oncology Program, the decision was made to include only randomized trials for Key Questions (KQs) 1 and 2. Therefore, this review consists of two parts: 1) a comparative effectiveness review of RCTs comparing surgery to SBRT for stage I non-small cell lung cancer in medically operable patients, and 2) an evidence map of available evidence comparing ablative therapies to other ablative therapies or surgery in either medically operable or inoperable patients.

The term *ablation* can be used to encompass a wide variety of treatment strategies, but in the context of our review, we specifically looked at the following therapies: radiofrequency ablation, cryoablation, microwave ablation, laser ablation, and brachytherapy. Acknowledging that SABR treatment is categorized as an ablative therapy (or implies ablative intent), the published literature suggests that SBRT and SABR are often used interchangeably and without distinction.⁷ While SBRT is a broad term used to describe the treatment modality itself, SABR is a better descriptor for the specific treatment that consists of applying highly dose-intensive radiation therapy to limited-volume targets with the effect of achieving local tumor control and even cure.⁸ For the purposes of this review, our key questions (and protocol) use the broader term SBRT to encompass both SBRT and SABR, but within the Results and Discussion we use the terms SBRT or SABR as reported by the authors of the primary studies.

The term *medically operable* was not defined *a priori* and we relied on the definition used by the individual studies as their predefined inclusion criteria for enrollment into the study. For the evidence map, we describe the population as reported in the primary studies and included individuals with medically operable as well as medically inoperable lung cancer.

KEY QUESTIONS

The following key questions were the focus of this review:

KQ1: Among adults with medically operable stage I non-small cell lung cancer, what are the benefits and harms of SBRT compared to surgery?

KQ2: Do benefits and harms of SBRT/SABR compared to surgery differ by patient characteristics (eg, age, comorbidities, performance status), tumor characteristics (size, location, stage), surgery characteristics (type of surgery [minimally invasive vs open],

type of resection [lobectomy, wedge resection, segmental resection, sleeve resection]), or SBRT characteristics (eg, dose, fractionation)?

KQ3: What are the quantity and characteristics of evidence assessing the comparative effects of ablative therapies as monotherapy or combined with other ablative therapies versus surgical, radiotherapy, or ablative therapies for patients with early stage I non-small cell lung cancer, by type of intervention, patient/tumor characteristics, study design, and outcomes?

PROTOCOL

A preregistered protocol for this review can be found on the PROSPERO international prospective register of systematic reviews (<http://www.crd.york.ac.uk/PROSPERO/>; registration number CRD42022377940).

DATA SOURCES AND SEARCHES

Two search strategies were developed, one to address KQs 1 and 2, and a second for KQ3. We searched MEDLINE and Embase from inception to September 2022. We supplemented these searches with a review of relevant systematic review bibliographies. Relevant systematic reviews were identified by keyword searches of the AHRQ, Cochrane, and VA ESP databases, suggestions by content experts, or reviews found and noted during abstract triage. We limited the searches to published and indexed articles involving human subjects available in the English language (see Appendix A for complete search strategies).

STUDY SELECTION

After duplicates were removed, citations were uploaded into DistillerSR.⁹ Using prespecified inclusion/exclusion criteria as described below in Table 1 for each KQ, titles and abstracts were screened independently by at least 1 reviewer for potential relevance. Any article excluded at the abstract level required confirmation by a second reviewer; articles included by either reviewer were advanced to the full-text review stage. At the full-text screening stage, 2 independent reviewers agreed on the final inclusion and exclusion decision. Disagreements were resolved by consensus among the review team. Articles that met eligibility criteria were included for data abstraction. A PRISMA flowchart documents the process of study selection and the total number of identified, included, and excluded studies. A complete list of citations excluded at full-text review can be found in Appendix B.

Table 1. Eligibility Criteria

	Key Questions 1 and 2	Key Question 3
Population	Adults, 18 years or older, with medically operable stage I non-small cell lung cancer	Adults, 18 years or older, with medically operable or inoperable stage I non-small cell lung cancer
Intervention	Stereotactic body radiation therapy (SBRT)/stereotactic ablative radiation therapy (SABR)	Non-surgical ablative treatment modalities: <ul style="list-style-type: none"> • Cryoablation • Radiofrequency ablation • Microwave ablation • Laser ablation • Brachytherapy

	Key Questions 1 and 2	Key Question 3
Comparator	Surgery, including wedge resection, segmental resection, lobectomy (including sleeve resection)	<ul style="list-style-type: none"> • Surgery, including wedge resection, segmental resection, lobectomy (including sleeve resection) • Ablative therapies: cryoablation, radiofrequency ablation, microwave ablation, laser ablation, brachytherapy • Radiotherapy (SBRT/SABR and conventional)
Outcomes	<ul style="list-style-type: none"> • Overall survival • Lung-cancer-specific survival • Local/regional recurrence/control • Systemic/distant recurrence/control • Overall/global quality of life • SBRT toxicity (grade 2-5 cough, pneumonitis, esophagitis) • Hospital readmissions • Short-term (<30 days) respiratory complications (pneumonia, hemothorax, pneumothorax, air leak, oxygen dependence at discharge) • Short-term (<30 days) cardiovascular complications (pneumonia, hemothorax, pneumothorax, air leak, oxygen dependence at discharge) • Long-term (>30 days) respiratory complications (cough, pneumonia, dyspnea, oxygen dependence) • Long-term (>30 days) pain (requiring medical intervention) 	<ul style="list-style-type: none"> • Overall survival • Lung-cancer-specific survival • Local/regional recurrence/control • Systemic/distant recurrence/control • Overall/global quality of life • Lung cancer specific quality of life validated scale item • SBRT toxicity (grade 2-5 cough, pneumonitis, esophagitis) • Hospital readmissions • Short-term (<30 days) respiratory complications (cough, pneumonia, hemothorax, pneumothorax, air leak, oxygen dependence at discharge) • Short-term (<30 days) cardiovascular complications (pneumonia, hemothorax, pneumothorax, air leak, oxygen dependence at discharge) • Post-ablative syndrome • Long-term (>30 days) respiratory complications (cough, pneumonitis, pneumonia, dyspnea, oxygen dependence)
Timing	Any	Any
Setting	Clinical	Clinical
Study Design	RCTs	RCTs and observational studies with a comparative arm

Abbreviations. RCT=randomized controlled trial.

DATA ABSTRACTION AND ASSESSMENT

Data from eligible studies were abstracted into customized DistillerSR databases by 1 reviewer and verified by a second reviewer. Any disagreements were resolved by consensus between the 2 reviewers or arbitrated by the study team.

For KQs 1 and 2, we abstracted the following information: trial characteristics (*eg*, inclusion/exclusion criteria), sample size, intervention and comparison characteristics, demographic information (*eg*, age, tumor stage), surgery characteristics, SBRT characteristics, and any information related to outcomes of interest. In addition to data from published articles, trial investigators were contacted and asked to provide data stratified by treatment arm (if available) to supplement the published data.

Two reviewers independently assessed risk of bias (RoB) using the Cochrane RoB 2 tool and resolved disagreements via discussion and consensus amongst the review team.¹⁰ For each study, we assessed the risk of bias for each domain as being low, high, or unclear. Ratings for all eligible studies for KQs 1 and 2 can be found in Appendix C.

For KQ3, we abstracted the following information: sample size, interventions and comparisons, demographic information (*eg*, age), country, study design, surgery and ablation therapy characteristics, and outcomes reported. As KQ3 consisted of an evidence map, no formal risk of bias assessment was performed for studies meeting eligibility criteria.

SYNTHESIS

For KQs 1 and 2, we identified a publication that conducted a quantitative analysis of data from the 2 trials and used this to inform our review. We evaluated the overall certainty of evidence for each outcome according to the GRADE approach, which considers 5 criteria (risk of bias, inconsistency, imprecision, publication bias, and indirectness). One author independently rated the certainty of evidence for each outcome as high, moderate, low, or very low using GRADEpro GDT.^{11,12} Any disagreement was resolved through group consensus. We evaluated the certainty of evidence for the following outcomes: overall survival, lung-cancer-specific survival, quality of life, and adverse events of grade 2 or higher. The summary of the evidence for the main outcomes is presented in a summary of findings table (Table 4), which provides key information regarding the best estimate of the magnitude of the effect in relative and absolute differences for each comparison of alternative management strategy, number of participants and studies, addressing each outcome, and a rating of the overall confidence in the estimates for each outcome.

For KQ3, we relied on data visualization techniques to summarize the data for the evidence map. No formal synthesis of study results was performed and no assessment of the quality of individual studies was conducted. We summarized the data narratively and provided visual graphics including tables and a bubble plot to summarize the key features of the studies. We mapped the results by types of studies, types of interventions versus comparisons, and types of outcomes. We used Microsoft Excel to create the figures and tables. We sought and iteratively incorporated feedback on visualization and usability from our review team.

RESULTS

KEY QUESTIONS 1 AND 2

KQ1: Among adults with medically operable stage I non-small cell lung cancer, what are the benefits and harms of stereotactic beam radiotherapy (SBRT) compared to surgery?

KQ2: Do benefits and harms of SBRT/SABR compared to surgery differ by patient characteristics (eg, age, comorbidities, performance status), tumor characteristics (size, location, stage), surgery characteristics (type of surgery [minimally invasive vs open], type of resection [lobectomy, wedge resection, segmental resection, sleeve resection]), or SBRT characteristics (eg, dose, fractionation)?

Literature Flow

The literature flow diagram (Figure 1) summarizes the results of the study selection process. The full list of excluded studies is available in Appendix B.

Literature Overview

Our search identified 2,959 potentially relevant citations. After title and abstract screening, 27 were moved forward to full-text review. Of those 27, we identified only 2 publications which met inclusion criteria for KQ1. Studies were excluded for the following reasons: ineligible publication type or study design (eg, commentaries or non-randomized studies), ineligible intervention or outcome (eg, radiotherapy vs chemotherapy or chemoradiation), and ineligible outcome (eg, treatment preferences). No eligible publications were identified that addressed KQ2.

One publication, Chang et al,¹³ pooled data from 2 randomized trials: the Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-Small Cell Lung Cancer (STARS) trial and the Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer (ROSEL) trial. Both trials had similar inclusion criteria (Table 2) and both were terminated early due to low recruitment. Both trials reported overall survival at 1 and 3 years, 3-year recurrence-free survival, and adverse events. The clinical trials had similar enrollment criteria with minor differences: histological confirmation was not required for the ROSEL trial as compared to the STARS trial, and follow-up intervals in the STARS trial were longer. Table 3 describes the STARS and ROSEL trial population characteristics and results individually, as well as the pooled results as reported in the Chang et al¹³ article. Data from the STARS trial were obtained from Clinicaltrials.gov, and data from the ROSEL trial were provided by trial investigators. The second publication, Louie et al,¹⁴ reported quality of life data from the ROSEL trial. Both publications were judged to have “some concerns” for risk of bias.

Figure 1. KQs 1 and 2 Literature Flowchart




Table 2. Overview of STARS (Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer) and ROSEL (Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer) Clinical Trial Information

Characteristics	STARS	ROSEL
Trial #	NCT00840749	NCT00687986
Country	28 sites in USA, China, and France (7 sites enrolled participants)	10 sites in Netherlands (4 sites enrolled participants)
Funding	Accuray (Industry)	Netherlands Organization for Health Research and Development
Inclusion criteria	<ul style="list-style-type: none"> • Patients with a histological confirmation of non-small cell cancer required by either biopsy or cytology. The following primary cancer types were eligible: squamous cell carcinoma, adenocarcinoma with or without BAC features, large cell carcinoma with or without neuroendocrine features, neuroendocrine carcinoma, bronchioloalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified. • Patients had to have appropriate staging studies identifying them as specific subsets of the revised IASCL stage IA or IB based on only 1 of the following combinations of TNM staging: T1, N0, M0 or T2 (≤ 4 cm), N0, M0. • Mandatory staging studies were done within 8 weeks prior to study entry. A PET/CT scan was required. • Patients with hilar or mediastinal lymph nodes with short axis diameter < 1 cm and no abnormal hilar or mediastinal uptake on PET were considered N0. Patients with > 1 cm short axis diameter of hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) were still eligible if directed tissue biopsy of all abnormally identified areas were negative for cancer. Solitary pulmonary lesions < 4 mm were not considered significant. • Patients had to be considered reasonable candidates for surgical resection of the primary tumor. Standard justification for deeming a patient medically operable based on pulmonary function for surgical resection of NSCLC included any of the following: baseline FEV1 $> 40\%$ 	<ul style="list-style-type: none"> • Patients with a cytological or histological diagnosis of stage IA non-cell lung cancer diagnosed in accordance with Dutch CBO guidelines. When no pathological diagnosis was available, a patient with a new or growing pulmonary lesion with radiological features consistent with malignancy AND a lesion showing uptake on a FDG-PET scan were eligible. • No evidence of regional or distant metastases on a standardized FDG-PET scan within 6 weeks of any protocol treatment • The medial extension of tumors at least 2 cm away from main and lobar bronchi, and also minimum of 1.5 cm from large peripheral blood vessels such as the aorta and main pulmonary artery. Lesions of at least 2 cm from the mediastinal pleura eligible if the responsible radiation oncologist judged that the specified normal tissue tolerance doses specified in the protocol were not to be exceeded. • Patients who were judged by a multi-disciplinary team to have 2 primary lung tumors (on the basis of clinical, radiological, FDG-PET and/or cyto-pathology findings) were eligible for randomization provided that both surgery and SRT could be performed in accordance with protocol requirements. • Patient had to be fit to undergo a complete surgical resection of the lesion in accordance with 2004 Dutch CBO guidelines. • Performance score of ECOG ≤ 2 was required before any treatment.

Characteristics	STARS	ROSEL
	<p>predicted, post-operative predicted FEV1 >30% diffusion capacity >40% predicted, absent baseline hypoxemia and/or hypercapnia, exercise oxygen consumption >50% predicted, absent severe pulmonary hypertension, absent severe cerebral, cardiac, or peripheral vascular disease, and absent severe chronic heart disease.</p> <ul style="list-style-type: none"> • Patients had to be ≥18 years of age • Patient's Zubrod performance status had to be Zubrod 0-2 	
Exclusion criteria	<ul style="list-style-type: none"> • Patients with primary tumors >4 cm • Patients with well-differentiated neuroendocrine carcinoma (carcinoid tumor) • Patients in whom acceptable SRT planning to meet minimal requirement of target coverage and dose-volume constraints of critical structures were not achievable • Evidence of regional or distant metastases, or synchronous primary or prior malignancy in the past 5 years other than non-melanomatous skin cancer or in situ cancer • Prior lung or mediastinal radiotherapy • Plans for concomitant local therapy (including standard fractionated radiotherapy and surgery) while on this protocol except at disease progression • Pregnant or lactating women (as treatment involved unforeseeable risks to the embryo or fetus) 	<ul style="list-style-type: none"> • Patients with any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease). • Prior or active malignancy (other than NSCLC) unless treated more than 3 years prior with curative intent and no recurrence, with the exception of non-melanoma skin cancers or in-situ cervical cancers • Prior chemotherapy or radiotherapy for the present diagnosis of NSCLC • Plans for concomitant treatment with any other experimental drug under investigation • Pregnancy • Men and women of child-bearing potential who were not using effective means of contraception for 6 months after treatment
Radiotherapy characteristics	<p>CyberKnife system (Accuray, Sunnyvale, CA, USA) was used for all radiotherapy sessions. Patients with peripherally located lesions (<i>ie</i>, those located >2 cm in any direction from the proximal bronchial tree, major vessels, oesophagus, heart, tracheal, vertebral body, pericardium, mediastinal pleural, and brachial plexus) received a total radiation dose of 54 Gy in three 18 Gy fractions (BED 151.2 Gy), calculated with a Monte Carlo or equivalent algorithms or its equivalent dose if other algorithms were used and heterogeneity correction. For central lesions (<i>ie</i>, those within 2 cm of these structures), 50 Gy in 4 12.5 Gy fractions (BED 112.5 Gy) was used. The</p>	<p>Linear-accelerator-based SABR from multiple vendors was used. Only lesions located 2 cm or more from the hilar structures on the diagnostic CT scan were eligible. A toxicity risk-adapted fractional scheme was used in which a total dose of 54 Gy in 3 18 Gy fractions (BED 151.3 Gy), calculated with a Monte Carlo or equivalent algorithms or its equivalent doses if other algorithms were used and heterogeneity correction, and given over 5–8 days; alternatively, a total dose of 60 Gy at 5 12 Gy fractions (BED 132.0 Gy), was given over 10–14 days (to account for different treatment-delivery practices in Dutch centers). The SABR dose prescription was chosen</p>

Characteristics	STARS	ROSEL
	<p>SABR dose was prescribed to the highest isodose line, which was required to cover 100% of the gross tumor volume (defined as visible disease in CT images with use of lung window) and more than 95% of the planning target volume (defined as the gross tumor volume plus a 3 mm margin). Coverage of 100% of the planning target volume by at least the prescription dose was encouraged. The normal tissue constraints were met for all cases. Treatment delivery was recommended to be complete within 5 days of its initiation.</p>	<p>such that 95% of the planning target volume, the internal target volume (based on four-dimensional CT), or other equivalent approaches to take tumor motion into consideration—plus a 3–5 mm margin for setup and motion uncertainty—would receive at least the nominal fraction dose, and 99% of the planning target volume would receive at least 90% of the fraction dose. The preferred maximum dose within the planning target volume was between 110% and 140% of the prescribed dose.</p>
Surgery characteristics	<p>Both open thoracotomy and video-assisted thoracotomy (VATS) were acceptable procedures. Surgery could consist of a lobectomy, sleeve resection, bi-lobectomy, or pneumonectomy as determined by the attending surgeon based on the operative findings.</p>	<p>Any anatomical surgical resection with lymph node dissection</p>

Abbreviations. BAC=bronchoalveolar carcinoma; BED=biologically effective dose; CBO=Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing (Dutch Institute for Healthcare Improvement); CT=computed tomography; ECOG=Eastern Cooperative Oncology Group; FEV=forced expiratory volume; FDG-PET=fluorodeoxyglucose-positron emission tomography; IASCL=International Association for the Study of Lung Cancer; SABR=stereotactic ablative radiotherapy; TNM=tumor, node, metastasis; USA =United States of America.

Overall Survival at 3 Years

Overall survival at 3 years, using pooled data from the STARS and ROSEL trials on 58 patients, was reported in 1 publication.¹³ When compared to surgery, the HR for 3-year overall survival was 0.14 (95% CI [0.017, 1.19]) based on follow-up of 35-40 months. However, both the radiotherapy and surgery arm had a very small number of deaths at 3 years, 1 in the SABR/SBRT arm and 5 in the surgery arm. Based on the limited number of individuals who underwent non-invasive surgery and based on both trials being terminated early, we are very uncertain about the effect of SABR/SBRT on overall survival at 3 years, as compared with surgery (very low certainty of evidence). A summary of findings is presented in Table 4.

Recurrence-Free Survival

Recurrence-free survival at 3 years was reported in the same publication¹³ using pooled data from the STARS and ROSEL trials. When compared to surgery, over a follow up of 35-40 months, the HR was 0.69 (95% CI [0.21, 2.29]). However, as outlined above, the effect of SABR/SBRT on recurrence-free survival at 3 years compared to surgery is very uncertain (very low certainty of evidence).

Adverse Events

The same publication reported on grade ≥ 3 adverse events, using pooled data on 58 patients from the STARS and ROSEL trials.¹³ When compared to surgery, the effect of SABR on grade ≥ 3 adverse events is very uncertain (Table 4). Specific adverse events as captured and reported by the individual trials are summarized in Table 3. Three grade ≥ 3 adverse events were reported across the 2 arms in the STARS cohort ($N = 36$). Sixteen grade ≥ 3 adverse events were reported across the 2 arms of the ROSEL cohort: 7 events in the SABR/SBRT arm ($N = 11$) and 9 events in the surgery arm ($N = 11$).

Quality of Life

One publication addressed quality of life (QoL) in participants ($N = 19$) treated with SABR compared to surgery, using data from the ROSEL trial.¹⁴ In this study, the following tools (administered at baseline, 3, 6, 12, 18, and 24 months) were used to assess QoL: the 30-item European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire (EORTC QLQ-C30, 13-item lung cancer supplement [LC-13] and the EuroQoL disease-specific questionnaire [EQ-5D]). Minimum thresholds of a 10-point decrease (for global and functional scales) and increase (for symptom scales and items) were used to denote a clinically meaningful difference. The following scales/items were reported: physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, global health status/QoL, fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial problems, coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts, and dyspnea. If at any point in the study period the participant had a ≥ 10 -point decrease from a prior rating, this was considered a meaningful event. In all comparisons, only global health status was found to be significantly worse on univariable Cox proportional hazard modeling for surgical patients when compared to SABR (HR = 0.19; 95% CI [0.04, 0.91]). However, this is based on a small number of patients with limited number of events and low rates of minimally invasive surgery (Table 5). Therefore, when compared to surgery, the effect of SABR on quality of life is very uncertain (very low certainty of evidence).

Table 3. Study Characteristics for All Eligible Trials Reporting Survival or Adverse Events

Characteristics & Outcomes	STARS*		ROSEL†		Chang (Pooled STARS & ROSEL)	
	SABR	Surgery	SABR	Surgery	SABR	Surgery
<i>Baseline Characteristics</i>						
N (% female)	36 (50)		11 (27)	11 (36)	31 (55)	27 (59)
Age	18-65: 16 (44) ≥65: 20 (56)		Median (IQR): 65 (61-71)	Median (IQR): 65 (62-72)	Mean (SD): 67.3 (9.2)	Mean (SD): 67.3 (8.2)
Median follow-up (IQR)	NR		Median (IQR): 42 months (20-54)		40.2 months (23.0 to 47.3)	35.4 months (18.9 to 40.7)
Tumor location N (%):	NR		Lower L: 5 (45) Upper L: 1 (9) Lower R: 2 (18) Middle R: 1 (9) Upper R: 2 (18)	Lower L: 2 (18) Upper L: 4 (36) Lower R: 0 (0) Middle R: 0 (0) Upper R: 5 (45)	Lower L: 7 (23) Upper L: 7 (23) Lower R: 5 (16) Middle R: 3 (10) Upper R: 9 (29)	Lower L: 4 (15) Upper L: 8 (30) Lower R: 1 (4) Middle R: 2 (7) Upper R: 12 (44)
Tumor stage: N (%)	NR*		NA = 11 ^l	T0: 1 (9) T1: 9 (82) T2: 1 (9)	T1a: 16 (52) T1b: 11 (35) T2a: 4 (13)	T1a: 18 (67) T1b: 8 (30) T2a: 1 (4)
Type of radiotherapy or surgery	54 Gy/3 Fx: 16 50 Gy/4 Fx: 4	NR	54 Gy in 3 18 Gy fractions over 5-8 days: 6 60 Gy at 5 12 Gy fractions over 10- 14 days: 5	Lobectomy: 10 Wedge resection: 1	--	Open lobectomy: 19 VATL: 5 VATB: 1 Wedge resection: 1 Aborted resection: 1
<i>Survival Outcomes</i>						
3-year overall survival (n/N)	31/36		10/11	10/11	95% (85 to 100) 30/31	79% (64 to 97) 22/27
					HR = 0.14 (0.017 to 1.190), <i>p</i> = 0.037	
3-year recurrence-free survival (n/N)	NR		9/11	8/11	86% (74 to 100) 26/31	80% (65–97) 21/27
					HR = 0.69 (0.21 to 2.290), <i>p</i> = 0.54	

Characteristics & Outcomes	STARS*		ROSEL†		Chang (Pooled STARS & ROSEL)	
	SABR	Surgery	SABR	Surgery	SABR	Surgery
<i>Adverse Events</i>						
Any treatment-related grade 2+ adverse events (n/N)	3/36		7/11	9/11	Grade 3+: 9.7% (-24 to 43)‡ 3/31	Grade 3+: 48% (21 to 75)‡ 13/27
Grade 2+ dyspnoea or cough (n/N)	0/36		5/11	6/11	Grade 3+: 6% (2/31)	Grade 3+: 19% (5/27)
SBRT toxicity	Grade 2+ pneumonitis (n/N)	0/36	0/11	0/11		NR
	Grade 2+ esophagitis	NR			NR	NR
Short-term (≤30 days)	Respiratory complications (pneumonia, hemothorax, pneumothorax, air leak, oxygen dependence at discharge)	NR			NR	NR
	Cardiovascular complications (MI/CVA/atrial fibrillation)	0/36	2/11	0/11		NR
	Hospital readmissions	NR			NR	NR
Long-term (>30 days)	Respiratory complications (cough, pneumonia, dyspnea, oxygen dependence)	NR			NR	NR
	Pain (requiring medical intervention)	NR			NR	NR

Notes. *Data taken from results posted on clinicaltrials.gov; trial investigators were contacted.

† Data was provided by principal investigator of ROSEL trial.

‡ Calculated by review authors.

§ Authors used International Association for the Staging of Lung Cancer (IASLC) 8th edition to stage participants.

¶ Authors used American Joint Commission on Cancer (AJCC) 7th edition to stage participants.

Abbreviations. CVA=cerebral vascular accident; Gy=Gray; HR=hazard ratio; IQR=interquartile range; L=left; MI=myocardial infarction; NA=not available; NR=not reported; R=right; ROSEL=Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer; SABR=stereotactic ablative radiotherapy; SD=standard deviation; STARS=Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer; VATB=video-assisted thoracotomy biopsy; VATL=video-assisted thoracotomy lobectomies.



Table 4. Certainty of Evidence for SABR/SBRT versus Surgery for Lung Cancer Outcomes

Outcome	Median Follow-up No. of Participants (Studies)	Relative Effect (95% CI)	Anticipated Absolute Effects (95% CI)		Certainty	What Happens
			Risk with Surgery	Risk Difference with SBRT/SABR		
3-year overall survival	35-40 months N = 58 (2 RCTs)	HR = 0.14 (0.017, 1.19)	815 per 1,000	157 more survived per 1,000 (31 fewer to 182 more)	⊕○○○ Very Low ^{a,b,c}	The evidence is very uncertain about the effect of SABR/SBRT on overall survival.
3-year recurrence-free survival	35-40 months N = 58 (2 RCTs)	HR = 0.69 (0.21, 2.29)	778 per 1,000	63 more survived per 1,000 (215 fewer to 171 more)	⊕○○○ Very Low ^{a,b,c}	The evidence is very uncertain about the effect of SABR/SBRT on recurrence-free survival.
Grade ≥3 adverse events	35-40 months N = 58 (2 RCTs)	RR = 0.27[†] (0.08, 0.87)	481 per 1,000	351 fewer had a Grade ≥3 adverse event per 1,000 (443 fewer to 63 fewer)	⊕○○○ Very Low ^{a,b,c}	The evidence is very uncertain about the effect of SABR/SBRT on grade ≥3 adverse events.
Reduction in quality of life	42 months N = 22 (1 RCT)	RR = 0.41[†] (0.11, 1.59)	800 per 1,000	472 fewer had a reduction in quality of life per 1,000 (712 fewer to 472 more)	⊕○○○ Very Low ^{a,b,c}	The evidence is very uncertain about the effect of SABR/SBRT on quality of life.

Notes. The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

† Calculated by review authors.

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

a. Downgraded for study limitations (lack of blinding of participants, investigators, and outcome adjudicators). Both studies terminated early due to issues with enrollment.

b. Downgraded 2 levels for imprecision due to very small number of events.

c. Downgraded for indirectness. The surgery group had low rates of minimally invasive surgical resection (eg, VATS).



Table 5. Study Characteristics for All Eligible Publications Reporting Quality of Life

Author, Year Risk of Bias Trial(s)	Characteristics & Outcomes	Surgery	SABR	Results
Louie, 2015 ¹⁴ Some concerns	N (% female)	11 (27)	11 (36)	-
	Median age (range)	65 (59-74)	65 (52-75)	-
ROSEL	Median follow-up (range)	42 months (6-61)		-
	Tumor stage: N (%)	T0: 1 (9) T1: 9 (82) T2:1 (9)	Not available	-
	*Reduction in quality of life	8/10	2/9	HR = 0.19 <i>p</i> = 0.038

Notes. *Quality of life data were not reported from 3 participants.

Abbreviations. HR=hazard ratio; ROSEL=Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer; SABR=stereotactic ablative radiotherapy.

KEY QUESTION 3

KQ3: What are the quantity and characteristics of evidence assessing the comparative effects of ablative therapies as monotherapy or combined with other ablative therapies versus surgical, radiotherapy or ablative therapies for patients with early stage I non-small cell lung cancer, by type of intervention, patient/tumor characteristics, study design, and outcomes?

Literature Flow

The literature flow diagram (Figure 2) summarizes the results of the study selection process. The full list of excluded studies is available in Appendix B.

Literature Overview

Of 3,095 potentially relevant citations after title and abstract screening, 131 were moved forward to full-text review. Of those 131, we identified 18 publications which met inclusion criteria for KQ3.

Data Visualization

Study Characteristics and Patient Population (Map 1)

No RCTs of ablation therapy were identified from our review; all the included studies were observational studies with a comparator group. Most publications were observational single-site retrospective cohort studies ($k = 10$),¹⁵⁻²⁴ while fewer used multisite retrospective data ($k = 2$).^{25,26}

The majority of the publications on ablative therapies were conducted in the US ($k = 9$)^{15,17,24,27-32}; other countries included China ($k = 3$),^{18,23,26} Japan ($k = 2$),^{19,25} Italy ($k = 2$),^{16,21} South Korea ($k = 1$)²⁰ and Germany ($k = 1$).²² Six publications used national US databases, including the National Cancer Database (NCDB) ($k = 4$)^{27,28,30,32} and the Surveillance, Epidemiology and End-Results Database (SEER) ($k = 2$).^{29,31} The sample size for the majority of studies was small (range 22-289), with the exception of the 6 large national database studies which included several thousand patients. Detailed information about characteristics for each publication can be found in Table 6.

All of the studies included older adults (mean or median age >60), with only 2 reporting a median or mean age <60.^{26,32} Most studies did not report on whether participants treated with various ablative treatments were felt to be medically operable or inoperable ($k = 8$)^{19,21,23,26-28,30,32} or reported including both medically operable and inoperable patients ($k = 5$).^{17,18,20,22,25} Only 2 studies reported on only medically operable individuals ($k = 2$)^{15,29} and 3 studies reported on only medically inoperable individuals ($k = 3$).^{16,24,31} None of the studies were conducted in Veterans. While most studies reported some information about tumor characteristics, there was no consistency across studies on which characteristics were reported. There was heterogeneity in reporting of tumor size (mean, median, or range provided) and cancer stage.

Interventions and Comparisons (Map 2)

In general, across studies, ablation was compared with surgery or radiotherapy. No studies of brachytherapy compared to surgery or radiotherapy (or other ablative therapies) were found. The interventions and comparisons for each study fell into 6 distinct comparison groups:

- ablation (type not specified or multiple types [cryoablation, laser ablation, radiofrequency ablation, microwave ablation] combined) versus radiotherapy ($k = 3$)^{27,28,32};
- radiofrequency ablation versus radiotherapy ($k = 3$)^{25,30,31};
- ablation (type not specified or multiple types combined) versus surgery ($k = 2$)^{24,29};
- microwave ablation versus surgery ($k = 4$)^{18,21,23,26};
- radiofrequency ablation versus surgery ($k = 4$)^{15-17,21};
- radiotherapy versus radiofrequency ablation versus surgery ($k = 2$)^{19,22}

Figure 3 shows the outcomes reported by comparisons made, and Figure 4 shows the outcomes reported, comparisons made, type of data used, and sample size for each publication.

Outcomes (Map 3)

With respect to outcomes, all publications reported overall survival ($k = 18$), most reported on local or regional recurrence ($k = 12$) and adverse events ($k = 11$), while fewer reported on lung-cancer-specific survival ($k = 8$) or distant recurrence ($k = 7$). We did not identify any publications that reported on quality of life. Figure 3 shows the outcomes that were reported by comparison group. A detailed breakdown of outcomes by study can be found in Table 7, and a detailed breakdown of specific adverse events reported by study can be found in Table 8.

Figure 2. KQ3 Literature Flowchart




Table 6. Detailed Characteristics for Eligible Publications for Key Question 3

Author, Year	Characteristics				Comparisons Analyzed						Interventions Included						
	Country	Single-site Administrative Data	Multi-site Administrative Data	National Database	Ablation (Combined) vs Radiotherapy	Radiofrequency Ablation vs Radiotherapy	Ablation (Combined) vs Surgery	Microwave vs Surgery	Radiofrequency Ablation vs Surgery	Radiotherapy vs Surgery	SBRT/SABR	Ablation (Not Specified)	Cryoablation	Radiofrequency Ablation	Microwave Ablation	Laser Ablation	Surgery
Ager, 2019 ²⁷	US		✓*	✓						✓	✓	✓				✓	
Alexander, 2011 ¹⁵	US	✓						✓					✓				✓
Ambrogi, 2015 ¹⁶	Italy	✓						✓					✓				✓
Baine, 2019 ²⁸	US		✓*	✓						✓		✓				✓	
Hsie, 2009 ¹⁷	US	✓						✓					✓				✓
Hu, 2021 ¹⁸	China	✓					✓							✓			✓
Iguchi, 2020 ¹⁹	Japan	✓							✓	✓			✓				✓
Kim, 2012 ²⁰	South Korea	✓						✓					✓				✓
Kwan, 2014 ²⁹	US		✓†			✓					✓						✓
Lam, 2018 ³⁰	US		✓*		✓					✓			✓				
Li, 2021 ³¹	US		✓†		✓					✓			✓				
Mendogni, 2020 ²¹	Italy	✓						✓						✓			✓
Ochiai, 2015 ²⁵	Japan		✓		✓					✓			✓				
Safi, 2015 ²²	Germany	✓							✓	✓			✓				✓
Uhlig, 2018 ³²	US		✓*	✓						✓		✓	✓			✓	
Wang, 2018 ²³	China	✓					✓							✓			✓
Yao, 2018 ²⁶	China		✓				✓							✓			✓
Zemlyak, 2010 ²⁴	US	✓				✓						✓	✓				✓

Notes. *National Cancer Database (NCDB)
 †Surveillance, Epidemiology and End-Results Database (SEER)



Figure 3. Outcomes Reported by Comparisons

	Overall Survival	Lung-cancer-specific Survival	Local/Regional Recurrence	Systemic/Distant Recurrence	Any Adverse Events	Quality of Life
Ablation (combined) vs Radiotherapy (k=3)	3	0	0	0	1	0
RFA vs Radiotherapy (k=3)	3	1	1	1	1	0
Ablation (combined) vs Surgery (k=2)	2	2	1	1	1	0
MWA vs Surgery (k=4)	4	3	4	2	3	0
RFA vs Surgery (k=4)	4	2	4	3	3	0
Radiotherapy vs RFA vs Surgery (k=2)	2	2	4	3	3	0

Notes. Combined indicates authors reported on outcomes based on different types of ablative therapy and not separately by specific ablative therapies.

Abbreviations. MWA=microwave ablation; RFA=radiofrequency ablation.

Figure 4. Evidence Map of Publications Reporting Ablation versus Radiotherapy or Ablation versus Surgery




Table 7. Outcomes Reported by Eligible Publications for Key Question 3

Author, Year	<i>Overall Survival</i>	<i>Lung-cancer-specific Survival</i>	<i>Local/Regional Recurrence</i>	<i>Systemic/Distant Recurrence</i>	<i>Any Adverse Events</i>	<i>Quality of Life</i>	<i>Short-term Cardiovascular Complications</i>	<i>Short-term Respiratory Complications</i>	<i>Long-term Respiratory Complications</i>	<i>Hospital Readmissions</i>
Ager, 2019 ²⁷	✓									
Alexander, 2011 ¹⁵	✓	✓	✓							
Ambrogi, 2015 ¹⁶	✓	✓	✓	✓	✓		✓	✓		
Baine, 2019 ²⁸	✓									
Hsie, 2009 ¹⁷	✓		✓	✓	✓				✓	
Hu, 2021 ¹⁸	✓		✓		✓		✓	✓		
Iguchi, 2020 ¹⁹	✓		✓		✓		✓	✓		
Kim, 2012 ²⁰	✓		✓	✓	✓				✓	
Kwan, 2014 ²⁹	✓	✓								
Lam, 2018 ³⁰	✓									
Li, 2021 ³¹	✓	✓								
Mendogni, 2020 ²¹	✓	✓	✓	✓						
Ochiai, 2015 ²⁵	✓		✓	✓	✓				✓	
Safi, 2015 ²²	✓		✓		✓		✓	✓	✓	✓
Uhlig, 2018 ³²	✓				✓					✓
Wang, 2018 ²³	✓	✓	✓		✓				✓	
Yao, 2018 ²⁶	✓	✓	✓	✓	✓		✓	✓		
Zemlyak, 2010 ²⁴	✓	✓	✓	✓	✓				✓	




Table 8. Specific Adverse Events Reported by Eligible Publications for Key Question 3

Author, Year	Short-term Cardiovascular Adverse Events							Short-term Respiratory Adverse Events						Long-term Respiratory Adverse Events						
	Atrial Fibrillation	Pulmonary Arterial Thrombosis	Myocardial Ischemia	Heart Failure	Pulmonary Embolism	Myocardial Infarction	Cardiac Arrest	Pneumonia	Chest Tube	Pneumothorax	Pleural Effusion	Pneumonitis	Respiratory Failure	Hemothorax	Air Leak	Pneumonia	Dyspnea	Pleural Effusion	Pneumonitis	Hemothorax
Ager, 2019 ²⁷																				
Alexander, 2011 ¹⁵																				
Ambrogi, 2015 ¹⁶	✓								✓											
Baine, 2019 ²⁸																				
Hsie, 2009 ¹⁷									✓											
Hu, 2021 ¹⁸	✓						✓	✓	✓	✓			✓							
Iguchi, 2020 ¹⁹		✓							✓	✓	✓									
Kim, 2012 ²⁰									✓											
Kwan, 2014 ²⁹																				
Lam, 2018 ³⁰																				
Li, 2021 ³¹																				
Mendogni, 2020 ²¹																				
Ochiai, 2015 ²⁵									✓	✓										
Safi, 2015 ²²	✓							✓	✓	✓			✓				✓	✓	✓	
Uhlig, 2018 ³²																				
Wang, 2018 ²³									✓	✓		✓								
Yao, 2018 ²⁶	✓		✓	✓					✓	✓		✓								
Zemlyak, 2010 ²⁴									✓	✓										

DISCUSSION

KEY MESSAGES

Key Questions 1 and 2

- Based on pooled data from the STARS and ROSEL trials comparing SABR/SBRT versus surgery, the evidence for 3-year survival, 3-year recurrence-free survival, quality of life, and adverse events is very uncertain (very low certainty of evidence).
 - Only 2 randomized trials, STARS and ROSEL, were identified that evaluated the role of SABR/SBRT compared to surgery for patients with medically operable stage I non-small cell lung cancer; both were terminated early due to lack of enrollment.
- No randomized trials were identified that examined if the benefits and harms of SABR/SBRT differ by patient characteristics, tumor characteristics, surgery characteristics, type of resection, or SBRT characteristics.
- There is an urgent need for randomized controlled trials to examine the comparative effectiveness of SABR/SBRT versus surgery for patients with medically operable stage I lung cancer.

We found insufficient evidence to inform the comparative effectiveness of SBRT/SABR versus surgery for stage I medically operable lung cancer. Our conclusions are based on 1 publication that pooled data from the STARS and ROSEL trials, which analyzed 58 persons with medically operable lung cancer (31 in the SABR group and 27 in the surgery group).¹³ Both trials were terminated early due to low accrual rates over a 5-year time period (2008-2013). One additional study of 22 individuals randomly assigned to SABR ($N = 11$) and surgery ($N = 11$) over a median follow-up of 42 months evaluated quality of life using the EORTC QLQ-C30, 13-item lung cancer supplement (LC-13), and EQ-5D, which were administered at baseline, 3, 6, 12, 18, and 24 months.¹⁴

Based on these 2 studies, we have very low certainty in the comparative effectiveness of SABR versus surgery for the following outcomes: 3-year overall survival, 3-year recurrence-free survival, adverse events, and quality of life. Of the 27 patients who received surgery, 19 had open lobectomies, 5 had video-assisted thoracotomy lobectomies, 1 had video-assisted thoracotomy biopsy (mediastinal lymph node biopsy positive for metastatic lung cancer), 1 had open wedge resection (benign lung nodule), and 1 had an aborted resection during the surgery due to disease progression. Our very low certainty in the pooled estimates is based on concerns of performance and detection bias across the 2 trials, very small number of events in the 2 intervention groups (only 7 total deaths over 3 years), and low rates of minimally invasive surgical resection in the surgery arm (indirectness). Therefore, there is insufficient evidence (very low certainty) of the effects of SABR versus surgery.

While the evidence base was very sparse and deemed insufficient to address the comparative effectiveness of SBRT versus surgery, we found no data evaluating KQ2: *ie*, whether benefits and harms of SBRT compared with surgery differed by patient, tumor characteristics, surgery, or SBRT characteristics. These characteristics are important as clinical decisions often include these factors, and variation in these characteristics may confound findings from observational studies.

Randomized trials, including the ongoing VA Cooperative Studies Program VALOR trial,⁶ are unlikely to be of sufficient size and design to adequately address all of these potential effect modifiers. However, researchers should include these components in future study designs and analyses.

These findings must be interpreted in the context of a large body of observational studies that have tried to address this question.³³ An important limitation of observational studies is that selection bias or confounding by indication may lead to inaccurate estimations of treatment effects. Confounding by indication is defined as a bias in the treatment-related outcome relationship due to the clinical reasons for the treatment. The indication for the treatment is based on physician and patient perceptions of disease severity and prognosis, including the presumed therapeutic effect of the intervention.³⁴ One approach to attempt to reduce this bias is the use of propensity-matched comparisons.

In the absence of evidence from randomized trials, investigators conducted a follow-up study of the STARS trial that used propensity matching.³⁵ This study was excluded during the full-text review process since it did not meet our required study design criteria for a RCT. In this single-center prospective observational study, the SABR group was re-accrued (using a revised STARS protocol) to allow for a larger sample size. Participants were then compared to a cohort of individuals that underwent video-assisted thorascopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND) using a protocol-specified propensity-matched comparison. Propensity matching was performed for the following covariates: age, tumor, histology, performance status, and the interaction of age and sex. The following outcomes were reported: overall survival at 3 and 5 years, progression-free survival, cancer-specific survival rates, patterns of failure, predictive value of PET scans, local recurrence-free survival, and incidence of grade 3 or worse toxicity. Overall, 10 deaths occurred, and 15 patients developed progression in the SABR group over a median follow up of 5.1 years. In the surgery group, there were 15 deaths and 6 recurrences or distant metastases. The authors reported that overall survival at 3 years in the SABR group was 91% (95% CI [85%, 98%]) compared with 91% (95% CI [76%, 98%]) in the propensity-matched VATS-LMND cohort. Furthermore, overall survival at 5 years in the SABR cohort was 87% (95% CI [79%, 95%]) compared with 84% (95% CI [76%, 93%]) in the surgery cohort. Based on these results, SABR was reported to be non-inferior to VATS-MLND for operable stage IA NSCLC.

The authors acknowledged that propensity score matching was performed only for known potential variables. Thus, there may still be bias due to residual confounding from unknown variables for which matching was not performed. Additional limitations as outlined by the authors included persistent concerns about selection bias of patients enrolled into the revised STARS study due to lack of randomization, and concerns about determination of medical operability since the surgical cohort was not treated under a fixed protocol. Notwithstanding the results showing similar outcomes for these 2 interventions suggesting that SBRT/SABR is equally effective as compared to surgery (specifically VATS L-MLND), there is an urgent need for randomized controlled trials examining the comparative effectiveness of these 2 treatment modalities to inform practitioners and patients of the optimal treatment for stage I medically operable lung cancer.

Key Question 3

- There are no RCTs of ablation therapies for stage I lung cancer. The following ablation therapies have been studied in non-randomized comparative studies: cryoablation, radiofrequency ablation, microwave ablation, and laser ablation. Radiofrequency ablation was the most commonly studied ablative therapy ($k = 11$).
- Six retrospective studies reported on ablation compared with SBRT/SABR:
 - Ablation (any type combined) versus SBRT/SABR ($k = 3$)
 - Radiofrequency ablation versus SBRT/SABR ($k = 3$)
- Ten retrospective studies reported on ablation compared with surgery:
 - Microwave ablation versus surgery ($k = 4$)
 - Radiofrequency ablation versus surgery ($k = 4$)
 - Ablation (any type combined) versus surgery ($k = 2$)
 - SBRT/SABR versus radiofrequency ablation versus surgery ($k = 2$)
- Two studies compared ablation with SBRT/SABR and surgery:
 - SBRT/SABR versus radiofrequency ablation versus surgery ($k = 2$)
- Most studies had 300 or fewer participants ($k = 12$) and were conducted in the US ($k = 9$), Europe ($k = 3$), China ($k = 3$), Japan ($k = 2$), and South Korea ($k = 1$), with the exception of 6 studies of administrative datasets (NCDB and SEER) and included 2,000-30,000 participants.
- The majority of studies reported on the following outcomes: overall survival ($k = 18$), disease-free survival ($k = 8$), local/regional recurrence ($k = 12$), and any adverse events ($k = 11$). No studies reported on quality of life.
- None of these studies were conducted in Veterans and most studies were conducted prior to widespread lung cancer screening.

Ablative therapies using thermal ablation (radiofrequency ablation, microwave ablation, and laser ablation), cryoablation, and brachytherapy are often used as modalities for palliative treatment or in individuals with inoperable cancers, but these therapies have increasingly been used in medically operable individuals with lung cancer.³⁶ Based on our evidence map, there were a limited number of comparative studies of ablative treatments versus surgery for lung cancer. Most of these studies did not specify medically operable patients and did not provide the stage of disease. Furthermore, studies commonly reported on ablation versus surgery or SBRT/SABR without providing data on specific ablative therapies and stratifying results by ablative technique. When individual studies of ablation were reported, the most common ablative therapy was radiofrequency ablation.

The majority of studies reported on overall and lung-cancer-specific survival as well as disease recurrence and treatment-related adverse events. For adverse events, most studies reported short-term respiratory complications ($k = 10$) or short-term cardiovascular complications ($k = 5$). Only 1 study reported long-term respiratory complications and 2 reported on hospital readmissions.

However, reporting of short-term versus long-term AEs was not well defined, and it was difficult to tell from the articles if there was a follow-up period in which adverse events were being recorded. There were no studies reporting on quality of life. Most studies did not specify medically operable patients and did not provide the stage of disease. Due to the heterogeneity of the studies with respect to patient populations (combining medically operable with non-medically operable patients), interventions (data not provided for specific ablative therapy), and study designs, we did not pool across studies and make inferences about effect size or overall certainty of evidence. Since several studies were using administrative datasets, there was also concern about “double counting.”

This evidence map for ablative therapies provides an overview of the scientific evidence, gaps in current knowledge, and needs of future research using visual analysis and graphic illustrations to help facilitate interpretation of results. This provides valuable information to researchers and funding organizations, as future clinical trials of different ablative therapies in individuals with medically operable lung cancer are needed to help inform practitioners and patients about the optimal role for ablative therapies within the framework of more established therapies such as surgery and SBRT.

LIMITATIONS

We acknowledge the following limitations of this evidence review. The results for the pooled analysis of the trials comparing SABR versus surgery were obtained from a publication of a post-hoc analysis of the 2 trials that had been terminated early due to lack of enrollment. We did not independently extract or pool the results from the trials, as the primary data were provided from the principal investigator for only 1 of the 2 trials despite attempts to obtain the results for each study. Furthermore, we focused our comparative effectiveness review on randomized controlled trials, in discussion with our nominating partner and TEP members. While numerous observational studies exist, including studies that utilize propensity matching, such study designs have not adequately addressed questions about comparative effectiveness and harms.

For the evidence map, we included observational studies with a comparator arm to better understand how ablative therapies have been evaluated as compared to standard therapies. Some of the retrospective studies of administrative datasets may have had overlapping years for patient selection and individuals may have been “double counted” across studies. Furthermore, these studies did not clearly distinguish medically operable versus inoperable persons and provided limited reporting on how individuals were selected to receive specific treatments. In this evidence map, we also did not provide information on effect size, direction of effect, or assessment of quality of studies to limit misinterpretation or over reliance on these studies for decision-making. These limitations notwithstanding, the evidence map outlines the current landscape of studies that have compared various ablative treatment strategies to inform the research agenda for future clinical trials.

APPLICABILITY

None of the studies were specific to VA populations. The ongoing VALOR RCT,⁶ funded by the VA Cooperative Studies Program (CSP #2005) aims to recruit 670 Veterans from at least 16 VA hospitals to compare stereotactic radiotherapy to standard lobectomy or segmentectomy for the treatment of medically operable, histologically confirmed, centrally or peripherally located stage I non-small cell lung cancers. Importantly, adequate recruitment and follow-up will be critical to

the success of this trial. Establishing equipoise and addressing patient treatment preferences will be an important barrier to overcome.³⁷ As management of lung cancer patients requires extensive multidisciplinary care and follow-up, interventions that support “buy-in” from different subspecialists and opportunities for shared decision-making as well as sustained efforts to promote recruitment into the trial will also be critical.

FUTURE RESEARCH

The results of our systematic review underscore the recognition that data from randomized controlled trials, especially that of the VA Cooperative Study VALOR,⁶ are critically needed to inform decisions around primary treatment for stage I lung cancer. The scarcity of randomized trial data is a major limitation in understanding the comparative effectiveness of different treatment strategies. This is particularly relevant given that the updated recommendations for expanded lung cancer screening incorporate surgical candidacy or willingness to undergo surgery as a prerequisite for offering screening.

Future studies should:

- Use consistent terminology or definitions for medically operable disease using standardized protocols for enrollment to further minimize selection bias or confounding by indication and provider bias for enrollment.
- Ensure adequate experience and training in the performance of minimally invasive surgery and ablative therapies.
- Ensure adequate enrollment and follow-up to have adequate sample size to detect clinically meaningful differences in overall and cancer-specific survival, tumor-free progression, adverse effects, quality of life, and long-term side effects (using consistent definitions).
- Be pragmatic in design to ensure that studies address the range of patients, tumors, and interventions under clinical consideration for individuals with newly diagnosed lung cancer (especially screen detected).
- Recruit patient engagement groups to understand barriers and seek solutions to randomization in trials of these vastly different treatments, and examine values and preferences, acceptability, and feasibility.
- Assess potential expansion of treatment options for stage I lung cancer to include SABR/SBRT and/or ablative therapies (potentially as a 3-arm trial).
- Explore how inclusion of screen-detected lesions would influence screening and treatment decisions and resultant net benefits. This includes use of less invasive therapies for small, indolent lung cancers among older sicker adults who would otherwise not have been candidates for screening or subsequent treatment.

CONCLUSIONS

In summary, the evidence is uncertain on the comparative effectiveness and harms of surgery versus SBRT/SABR for adults with medically operable lung cancer. Lung cancer is among the most common and lethal cancers globally. Those with early stage, especially cancers detected by

low-dose CT screening, have the highest chance for effective therapies and mortality reduction. While surgery has been commonly considered the treatment strategy of choice for medically operable disease, stereotactic radiotherapy has emerged as an alternative treatment strategy. Given current evidence uncertainty, overall disease burden, and the growing role of lung cancer screening, robust randomized controlled trial results are needed. Furthermore, the field of ablative therapies continues to innovate and expand and is becoming more widely studied. There is a critical need for robust evidence on comparative treatment effects as well as patient preferences and values to inform the management of patients with medically operable stage I non-small cell lung cancer.

REFERENCES

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin.* Jan 2023;73(1):17-48. doi:10.3322/caac.21763
2. Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. *BMJ.* Mar 30 2022;376:e069008. doi:10.1136/bmj-2021-069008
3. Franchio C. Help va spread awareness about lung cancer symptoms and screening. . 2021. <https://blogs.va.gov/VAntage/97439/help-va-spread-awareness-about-lung-cancer-symptoms-and-screening>
4. Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. *Cancer.* Feb 15 2018;124(4):667-678. doi:10.1002/cncr.31196
5. U. S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA.* Mar 9 2021;325(10):962-970. doi:10.1001/jama.2021.1117
6. (CSP) VCSP. CSP #2005 Surgery or Stereotactic Radiotherapy for Early-Stage Lung Cancer. Updated March 2021. https://www.vacsp.research.va.gov/CSP_2005/CSP_2005.asp
7. Lapen K, Mathis, N.J., Tsai, C.J., Yang, J.T., Gillespie, E.F. Stereotactic Body Radiation Therapy (SBRT) vs Stereotactic Ablative Radiation Therapy (SABR): Does Terminology Differentiate Treatment Intent in Metastatic Cancer? https://www.appliedradiology.org/courses/4549%2FPDF%2FARO_12-21_LapenCME.pdf
8. Loo BW, Jr., Chang JY, Dawson LA, et al. Stereotactic ablative radiotherapy: what's in a name? *Pract Radiat Oncol.* Jan-Mar 2011;1(1):38-9. doi:10.1016/j.prro.2010.07.001
9. DistillerSR. Evidence Partners Inc., Manotick, Ontario, Canada. Accessed Sept.-Dec. 2022, <https://www.evidencepartners.com/>.
10. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* Aug 28 2019;366:l4898. doi:10.1136/bmj.l4898
11. Schunemann H BJ, Guyatt G, Oxman A. *GRADE Handbook.* <https://gdt.gradepro.org/app/handbook/handbook.html#:~:text=The%20GRADE%20handbook%20describes%20the,www.gradeworkinggroup.org>.
12. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime. Accessed Sept.-Dec. 2022,
13. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. *The Lancet Oncology.* 2015;16(6):630-7. Comment in: *Lancet Oncol.* 2015 Jun;16(6):597-8 PMID: 25981817 [<https://www.ncbi.nlm.nih.gov/pubmed/25981817>] Comment in: *Lancet Oncol.* 2015 Aug;16(8):e370-1 PMID: 26248836 [<https://www.ncbi.nlm.nih.gov/pubmed/26248836>] Comment in: *Lancet Oncol.* 2015 Aug;16(8):e371-2 PMID: 26248837 [<https://www.ncbi.nlm.nih.gov/pubmed/26248837>] Comment in: *Lancet Oncol.* 2015 Aug;16(8):e372-3 PMID: 26248838 [<https://www.ncbi.nlm.nih.gov/pubmed/26248838>] Comment in: *Lancet Oncol.* 2015 Aug;16(8):e372 PMID: 26248839 [<https://www.ncbi.nlm.nih.gov/pubmed/26248839>] Comment in: *Lancet Oncol.* 2015 Aug;16(8):e373-4 PMID: 26248840 [<https://www.ncbi.nlm.nih.gov/pubmed/26248840>] Comment in: *Lancet Oncol.* 2015

- Aug;16(8):e374-5 PMID: 26248841 [<https://www.ncbi.nlm.nih.gov/pubmed/26248841>]
 Comment in: J Thorac Cardiovasc Surg. 2015 Sep;150(3):468-71 PMID: 26259993
[\[https://www.ncbi.nlm.nih.gov/pubmed/26259993\]](https://www.ncbi.nlm.nih.gov/pubmed/26259993) Comment in: Lancet Oncol. 2015
 Sep;16(9):e422 PMID: 26370343 [<https://www.ncbi.nlm.nih.gov/pubmed/26370343>]
 Erratum in: Lancet Oncol. 2015 Sep;16(9):e427 PMID: 26370351
[\[https://www.ncbi.nlm.nih.gov/pubmed/26370351\]](https://www.ncbi.nlm.nih.gov/pubmed/26370351) Comment in: Strahlenther Onkol.
 2015 Dec;191(12):988-90 PMID: 26459463
[\[https://www.ncbi.nlm.nih.gov/pubmed/26459463\]](https://www.ncbi.nlm.nih.gov/pubmed/26459463) Comment in: Lancet Oncol. 2016
 Feb;17(2):e41-2 PMID: 26868347 [<https://www.ncbi.nlm.nih.gov/pubmed/26868347>]
 Comment in: Lancet Oncol. 2016 Feb;17(2):e42-3 PMID: 26868349
[\[https://www.ncbi.nlm.nih.gov/pubmed/26868349\]](https://www.ncbi.nlm.nih.gov/pubmed/26868349).
 doi:[https://dx.doi.org/10.1016/S1470-2045\(15\)70168-3](https://dx.doi.org/10.1016/S1470-2045(15)70168-3)
14. Louie AV, van Werkhoven E, Chen H, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2015;117(1):44-8. Comment in: Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):927-930 PMID: 27869093 [<https://www.ncbi.nlm.nih.gov/pubmed/27869093>]. doi:<https://dx.doi.org/10.1016/j.radonc.2015.08.011>
 15. Alexander ES, Dupuy DE, Machan JT, Ng T, Breen L, DiPetrillo T. Cost and effectiveness of radiofrequency ablation versus surgery for Stage I non-small cell lung cancer in the elderly: Is less more? *Journal of Vascular and Interventional Radiology*. 2011;22(3 SUPPL. 1):S54. 36th Annual Scientific Meeting of the Society of Interventional Radiology, SIR 2011 - IR Rising: Leading Image-Guided Medicine. Chicago, IL United States. Sponsor: Navylist Medical . (var.pagings). doi:<https://dx.doi.org/10.1016/j.jvir.2011.01.136>
 16. Ambrogi MC, Fanucchi O, Dini P, et al. Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer. *European Respiratory Journal*. 2015;45(4):1089-1097. doi:<https://dx.doi.org/10.1183/09031936.00188014>
 17. Hsie M, Morbidini-Gaffney S, Kohman LJ, Dexter E, Scalzetti EM, Bogart JA. Definitive treatment of poor-risk patients with stage i lung cancer: A single institution experience. *Journal of Thoracic Oncology*. 2009;4(1):69-73. doi:<https://dx.doi.org/10.1097/JTO.0b013e3181914d3a>
 18. Hu H, Zhai B, Liu R, Chi J. Microwave Ablation Versus Wedge Resection for Stage I Non-small Cell Lung Cancer Adjacent to the Pericardium: Propensity Score Analyses of Long-term Outcomes. *CardioVascular and Interventional Radiology*. 2021;44(2):237-246. doi:<https://dx.doi.org/10.1007/s00270-020-02601-7>
 19. Iguchi T, Hiraki T, Matsui Y, et al. Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non-Small-Cell Lung Cancer: A Single-Center Evaluation. *Journal of Vascular and Interventional Radiology*. 2020;31(7):1044-1051. doi:<https://dx.doi.org/10.1016/j.jvir.2019.11.035>
 20. Kim SR, Han HJ, Park SJ, et al. Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer. *European journal of radiology*. 2012;81(2):395-9. doi:<https://dx.doi.org/10.1016/j.ejrad.2010.12.091>
 21. Mendogni P, Daffre E, Rosso L, et al. Percutaneous lung microwave ablation versus lung resection in high-risk patients. A monocentric experience. *Acta bio-medica : Atenei*

- Parmensis*. 2020;91(10S):e2020002. doi:<https://dx.doi.org/10.23750/abm.v91i10-S.10342>
22. Safi S, Rauch G, Op Den Winkel J, et al. Sublobar Resection, Radiofrequency Ablation or Radiotherapy in Stage i Non-Small Cell Lung Cancer. *Respiration*. 2015;89(6):550-557. doi:<https://dx.doi.org/10.1159/000381555>
 23. Wang Y, Liu B, Cao P, et al. Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer. *Thoracic Cancer*. 2018;9(11):1376-1382. doi:<https://dx.doi.org/10.1111/1759-7714.12842>
 24. Zemlyak A, Moore WH, Bilfinger TV. Comparison of Survival after Sublobar Resections and Ablative Therapies for Stage I Non-Small Cell Lung Cancer. *Journal of the American College of Surgeons*. 2010;211(1):68-72. doi:<https://dx.doi.org/10.1016/j.jamcollsurg.2010.03.020>
 25. Ochiai S, Yamakado K, Kodama H, et al. Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller. *International Journal of Clinical Oncology*. 2015;20(3):499-507. doi:<https://dx.doi.org/10.1007/s10147-014-0741-z>
 26. Yao W, Lu M, Fan W, et al. Comparison between microwave ablation and lobectomy for stage I non-small cell lung cancer: a propensity score analysis. *International Journal of Hyperthermia*. 2018;34(8):1329-1336. doi:<https://dx.doi.org/10.1080/02656736.2018.1434901>
 27. Ager BJ, Scheick S, Gruhl JD, Tao R, Kokeny KE, Hitchcock YJ. Stereotactic Body Radiotherapy versus Local Tumor Ablation for Early-Stage Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*. 2019;104(1):233-234. 2019 Thoracic Cancers Symposium. San Diego United States. doi:<https://dx.doi.org/10.1016/j.ijrobp.2019.01.020>
 28. Baine MJ, Sleightholm R, Neilsen BK, et al. Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non-Small Cell Lung Cancer. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2019;17(5):450-458. doi:<https://dx.doi.org/10.6004/jnccn.2018.7269>
 29. Kwan SW, Mortell KE, Talenfeld AD, Brunner MC. Thermal ablation matches sublobar resection outcomes in older patients with early-stage non-small cell lung cancer. *J Vasc Interv Radiol*. Jan 2014;25(1):1-9 e1. doi:10.1016/j.jvir.2013.10.018
 30. Lam A, Yoshida EJ, Bui K, Fernando D, Nelson K, Abi-Jaoudeh N. A National Cancer Database Analysis of Radiofrequency Ablation versus Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer. *Journal of Vascular and Interventional Radiology*. 2018;29(9):1211-1217.e1. doi:<https://dx.doi.org/10.1016/j.jvir.2018.04.029>
 31. Li M, Xu X, Qin Y, et al. Radiofrequency ablation vs. stereotactic body radiotherapy for stage IA non-small cell lung cancer in nonsurgical patients. *Journal of Cancer*. 2021;12(10):3057-3066. doi:<https://dx.doi.org/10.7150/jca.51413>
 32. Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. *Radiology*. 2018;289(3):862-870. Comment in: *Radiology*. 2018 Dec;289(3):871-872 PMID: 30226452 [<https://www.ncbi.nlm.nih.gov/pubmed/30226452>] Comment in: *Radiology*. 2019 Feb;290(2):574-575 PMID: 30599098

- [<https://www.ncbi.nlm.nih.gov/pubmed/30599098>].
doi:<https://dx.doi.org/10.1148/radiol.2018180979>
33. Deng HY, Wang YC, Ni PZ, et al. Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer. *Eur J Cardiothorac Surg*. Feb 1 2017;51(2):203-210. doi:10.1093/ejcts/ezw272
 34. Joseph KS, Mehrabadi, A. & Lisonkova, S. Confounding by Indication and Related Concepts. *Curr Epidemiol Rep*. 2014;1(March 2014):1-8.
doi:<https://doi.org/10.1007/s40471-013-0004-y>
 35. Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. *Lancet Oncol*. Oct 2021;22(10):1448-1457. doi:10.1016/S1470-2045(21)00401-0
 36. Jiang B, McClure MA, Chen T, Chen S. Efficacy and safety of thermal ablation of lung malignancies: A Network meta-analysis. *Ann Thorac Med*. Oct-Dec 2018;13(4):243-250. doi:10.4103/atm.ATM_392_17
 37. Franks KN, McParland L, Webster J, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. *Eur Respir J*. Nov 2020;56(5)doi:10.1183/13993003.00118-2020

APPENDIX A. SEARCH STRATEGIES

MEDLINE & EMBASE

Key Question 1&2

	Search Terms
1	Exp lung neoplasms/di, rt, su, th [diagnosis, radiotherapy, surgery, therapy]
2	Non-small-cell lung carcinomas.tw
3	Non-small cell lung cancer.tw
4	Nsclc.tw
5	OR/1-4
6	Radiation Dose Hypofractionation/ or (radiotherapy minibeam\$1 or radiation hypofractionated dose or radiation dose hypofractionation or hypofractionated radiation therapy or short?course radiation therapy).ti,ab.
7	dose fractionation/ or dose response relationship, radiation/ or radiotherapy dosage/
8	((radiotherapy* or radiat*) adj2 (dose or dosage or regimen* or schedule*)).tw.
9	hypofractionat*.mp.
10	hypo-fraction*.mp.
11	multi-fraction*.tw.
12	(hypo adj3 fraction*).tw.
13	Stereotactic body radiation therapy/ or SBRT.mp.
14	Stereotactic ablative body radiation therapy/ or SABR.mp.
15	(Stereotactic body radiation therapy or SBRT).tw.
16	(Stereotactic ablative body radiation therapy or SABR).tw.
17	Exp radiosurgery/
18	Or/6-17
19	Lung cancer terms and SBRT (5 and 18)
20	(thoracic surg*).tw,kw.
21	Lobectomy.tw
22	Video-assisted thoracoscopic surgery.tw
23	VATS.tw
24	Posterolateral thoracotomy.tw
25	Sublobar resection.tw
26	Segmentectomy.tw
27	Sublobectomy or wedge resection.tw
28	Segmental resection.tw
29	Limited resection.tw
30	Or/20-29
31	Lung cancer terms and Surgery (5 and 30)
32	Randomized controlled trial.pt. or randomized.mp. or placebo.mp.
33	Randomized controlled trial/ or random allocation/ or double-blind method/ or single-blind method/ or placebos/

34	('clinical trial' or 'randomized controlled study' or 'randomized controlled trial' or 'double blind clinical study' or 'single blind clinical study' or 'random allocation').ti,ab.
35	Or/32-34
36	19 or 31
37	35 and 36
38	Limit 37 to English language
39	Limit 38 to yr="2000-current"

Key Question 3

	Search Terms
1	Exp lung neoplasms/di, rt, su, th [diagnosis, radiotherapy, surgery, therapy]
2	Non-small-cell lung carcinomas.tw
3	Non-small cell lung cancer.tw
4	Nsclc.tw
5	OR/1-4
6	exp cryosurgery/
7	exp Radiofrequency Therapy/
8	(((radiofrequency or microwave) adj1 ablation) or brachytherapy).tw.
9	Exp brachytherapy/
10	(Microwaves exp Mesh Term/ OR microwaves.tw OR "Radio Waves" exp Mesh Term/ or Radiowaves.tw or "radio waves".tw) OR (("Radiowaves".tw OR "Radio Waves".tw) AND "ablation".tw)
11	(Cryoablation.tw OR Cryoprobes.tw OR Cryotherapy Mesh Term/ OR Cryotherapy.tw OR Cryosurgery.tw OR Cryogen*.tw)
12	Or/6-11
13	Lung cancer with other treatment (5 and 12)
14	Limit 13 to English language
15	Limit 14 to yr = "2000-current"

AHRQ, COCHRANE, VA ESP KEYWORDS

Lung cancer, lung malignancy, malignant, lung, radiotherapy, ablative therapy

APPENDIX B. EXCLUDED STUDIES

KEY QUESTIONS 1 & 2

1. Aridgides P, Bogart J. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. *Thoracic Surgery Clinics*. 2016;26(3):261-269. *Ineligible publication type*
2. Bahig H, Chen H, Louie AV. Surgery versus SABR for early stage non-small cell lung cancer: The moving target of equipoise. *Journal of Thoracic Disease*. 2017;9(4):953-956. *Ineligible publication type*
3. Chen W, Lin Q, Sun X, et al. A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy. *Journal of Clinical Oncology*. 2017;35(15 Supplement 1). *Ineligible study design*
4. Choy H, Chakravarthy A, Kim JS. Radiation therapy for non-small cell lung cancer (NSCLC). *Cancer treatment and research*. 2001;105:121-48. *Ineligible publication type*
5. Fernando HC, Timmerman R. American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer. *The Journal of thoracic and cardiovascular surgery*. 2012;144(3):S35-8. *Ineligible publication type*
6. Franks KN, McParland L, Webster J, et al. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. *The European respiratory journal*. 2020;56(5). *Ineligible outcome*
7. Gerard M, Lerouge D, Le Guevelou J, Thariat J. Stereotaxic ablative radiotherapy in stage 1 non-small-cell lung cancer: Results of the phase 3 randomized trial "CHISEL". *Bulletin du Cancer*. 2020;107(2):145-147. *Ineligible language*
8. Guckenberger M. SBRT versus lobectomy in stage I NSCLC: Knowns, unknowns and its interpretation. *Journal of Thoracic Disease*. 2016;8(9):2305-2309. *Ineligible publication type*
9. Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2017;123(2):276-281. *Ineligible intervention*
10. Herrmann MKA, Bloch E, Overbeck T, et al. Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC--treatment results after long-term follow-up and literature overview. *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique*. 2011;15(2):81-8. *Ineligible intervention*
11. Love SM, Hardman G, Mashar R, Shah RD. Is it time for SABR to overtake surgery as the treatment of choice for stage I non-small cell lung cancer? *Annals of Translational Medicine*. 2016;4(24):535. *Ineligible publication type*
12. Macchi M, Belfiore MP, Floridi C, et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. *Medical Oncology*. 2017;34(5):96. *Ineligible intervention*

13. Nieder C, Andratschke NH, Guckenberger M. A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? *Annals of translational medicine*. 2015;3(11):148. *Ineligible publication type*
14. Onaitis MW, Salama J. Surgery versus stereotactic body radiation therapy for operable stage i non-small cell lung cancer: Can we achieve equipoise? *Journal of Thoracic and Cardiovascular Surgery*. 2016;152(1):1-2. *Ineligible publication type*
15. Parashar B, Port J, Arora S, et al. Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer. *Brachytherapy*. 2015;14(5):648-54. *Ineligible study design*
16. Robinson C, Kruser TJ, Owen D, Salama J, Daly ME. Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*. 2022;112(5):1067-1070. *Ineligible publication type*
17. Roesch J, Andratschke N, Guckenberger M. SBRT in operable early stage lung cancer patients. *Translational lung cancer research*. 2014;3(4):212-24. *Ineligible publication type*
18. Rusthoven CG, Kavanagh BD, Karam SD. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. *Annals of translational medicine*. 2015;3(11):149. *Ineligible publication type*
19. Samson P, Keogan K, Crabtree T, et al. Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients. *Lung cancer (Amsterdam, Netherlands)*. 2017;103:6-10. *Ineligible study design*
20. Seo Y-S, Kim HJ, Wu HG, Choi SM, Park S. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. *Thoracic cancer*. 2019;10(6):1489-1499. *Ineligible study design*
21. Sepesi B, Rice DC, Heymach JV, Vaporciyan AA, Swisher SG. Stage I lung cancer-to operate or to radiate? That is the question. *Journal of Thoracic Disease*. 2016;8(9):2324-2327. *Ineligible publication type*
22. Shi XX, Pang HW, Ren PR, Sun XY, Wu JB, Lin S. Template-assisted¹⁹²Ir-based stereotactic ablative brachytherapy as a neoadjuvant treatment for operable peripheral non-small cell lung cancer: A phase I clinical trial. *Journal of Contemporary Brachytherapy*. 2019;11(2):162-168. *Ineligible study design*
23. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? *Thoracic Surgery Clinics*. 2013;23(3):369-381. *Ineligible publication type*
24. Teke ME, Sarvestani AL, Hernandez JM, Fernando HC, Timmerman RD. A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). *Annals of surgical oncology*. 2022;29(8):4686-4687. *Ineligible publication type*
25. Videtic GM, Paulus R, Singh AK, et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral

Non-Small Cell Lung Cancer. *International journal of radiation oncology, biology, physics*. 2019;103(5):1077-1084. *Ineligible intervention*

KEY QUESTION 3

1. Abdel-Aaty H, Bakr R, El-Mahallawy I, El-Helbawy R, Hussein S, Abdel-Tawab A. Cryotherapy and electrocautery in the management of malignant endobronchial neoplasms. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2019;68(2):184-191. *Ineligible population*
2. Alexander ES, Hankins CA, MacHan JT, Healey TT, Dupuy DE. Rib fractures after percutaneous radiofrequency and microwave ablation of lung tumors: Incidence and relevance. *Radiology*. 2013;266(3):971-978. *Ineligible outcome*
3. Ambrogi MC, Dini P, Melfi F, Mussi A. Radiofrequency ablation of inoperable non-small cell lung cancer. *Journal of Thoracic Oncology*. 2007;2(5 SUPPL.1):S2-S3. *Ineligible outcome*
4. Ambrogi MC, Fontanini G, Cioni R, Faviana P, Fanucchi O, Mussi A. Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: Results of a pilot study. *Journal of Thoracic and Cardiovascular Surgery*. 2006;131(5):1002-1006. *Ineligible population*
5. Amjadi K, Voduc N, Cruysberghs Y, et al. Impact of interventional bronchoscopy on quality of life in malignant airway obstruction. *Respiration*. 2008;76(4):421-428. *Ineligible intervention*
6. Asimakopoulos G, Beeson J, Evans J, Maiwand MO. Cryosurgery for malignant endobronchial tumors: Analysis of outcome. *Chest*. 2005;127(6):2007-2014. *Ineligible population*
7. Aufranc V, Farouil G, Abdel-Rehim M, et al. Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation. *Diagnostic and Interventional Imaging*. 2019;100(12):781-791. *Ineligible population*
8. Baisi A, Raveglia F, De Simone M, Cioffi U. Recurrence after radiofrequency ablation for stage i non-small cell lung cancer. *Annals of Thoracic Surgery*. 2012;94(5):1788-1789. *Ineligible study design*
9. Beland M, Mueller PR, Gervais DA. Thermal Ablation in Interventional Oncology. *Seminars in Roentgenology*. 2007;42(3):175-190. *Ineligible study design*
10. Birdas TJ, Koehler RPM, Colonias A, et al. Sublobar resection with brachytherapy versus lobectomy for stage Ib nonsmall cell lung cancer. *Annals of Thoracic Surgery*. 2006;81(2):434-439. *Ineligible intervention*
11. Botsa EI, Thanou IL, Papatheodoropoulou AT, Thanos LI. Thermal ablation in the management of adrenal metastasis originating from non-small cell lung cancer: A 5-year single-center experience. *Chinese Medical Journal*. 2017;130(17):2027-2032. *Ineligible population*
12. Cackler S, Abbas G. RFA is an effective alternative to lobectomy for lung cancer. *JAAPA: official journal of the American Academy of Physician Assistants*. 2009;22(1):25-8. *Ineligible study design*
13. Canak V, Zaric B, Milovancev A, et al. Combination of interventional pulmonology techniques (Nd:YAG laser resection and brachytherapy) with external beam radiotherapy in the treatment of lung cancer patients with Karnofsky Index <= 50. *Journal of BUON*. 2006;11(4):447-456. *Ineligible intervention*

14. Carrafiello G, Mangini M, Fontana F, et al. Complications of microwave and radiofrequency lung ablation: personal experience and review of the literature. *La Radiologia medica*. 2012;117(2):201-213. *Ineligible study design*
15. Chella A, Ambrogi MC, Ribechini A, et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: A prospective randomized study. *Lung Cancer*. 2000;27(3):169-175. *Ineligible intervention*
16. Chen S, Sheng Z, Huang N. Radiofrequency Ablation Combined with Radioactive Seed Implantation for Nonsmall Cell Lung Cancer. *Journal of healthcare engineering*. 2022;2022:4016081. *Ineligible population*
17. Chi J, Ding M, Shi Y, et al. Comparison study of computed tomography-guided radiofrequency and microwave ablation for pulmonary tumors: A retrospective, case-controlled observational study. *Thoracic Cancer*. 2018;9(10):1241-1248. *Ineligible population*
18. Choe YH, Kim SR, Lee KS, et al. The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer. *European Journal of Cancer*. 2009;45(10):1773-1779. *Ineligible population*
19. Choe YH, Rhee YK, Park SJ, et al. Therapeutic value of image-guided ablations as treatment alternatives in non-small cell lung cancer. *Respirology*. 2009;14(SUPPL. 3):A248. *Ineligible publication type*
20. Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). *The Journal of thoracic and cardiovascular surgery*. 2013;145(3):692-9. *Ineligible intervention*
21. D'Amico TA. Local control without resection. *The Journal of thoracic and cardiovascular surgery*. 2003;125(4):787-8. *Ineligible publication type*
22. Davis JN, Medbery C, Sharma S, Danish A, Mahadevan A. The RSSearchTM Registry: Patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. *Radiation Oncology*. 2013;8(1):275. *Ineligible population*
23. DiRico M, Roy SG, Berry G, Brahmakulam F. RADIOFREQUENCY AND CRYOABLATION FOR MALIGNANT LUNG NODULES IN A COMMUNITY SETTING. *Chest*. 2020;158(4 Supplement):A1947. *Ineligible publication type*
24. Donington JS. Radiofrequency ablation in high-risk stage i non-small cell lung cancer. *Cancer*. 2015;121(19):3393-3394. *Ineligible publication type*
25. Dupuy D, Fernando H, Hillman S, et al. Radiofrequency ablation of stage 1A NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance), an NCI funded multicenter trial. *Chest*. 2013;144(4 MEETING ABSTRACT). *Ineligible publication type*
26. Dupuy DE. Science to practice: Microwave ablation compared with radiofrequency ablation in lung tissue - Is microwave not just for popcorn anymore? *Radiology*. 2009;251(3):617-618. *Ineligible publication type*
27. Dupuy DE. Treatment of medically inoperable non-small-cell lung cancer with stereotactic body radiation therapy versus image-guided tumor ablation: can interventional radiology compete? *Journal of vascular and interventional radiology : JVIR*. 2013;24(8):1139-45. *Ineligible study design*
28. Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American

- College of Surgeons Oncology Group Z4033 (Alliance) trial. *Cancer*. 2015;121(19):3491-3498. *Ineligible intervention*
29. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. *AJR American journal of roentgenology*. 2000;174(1):57-9. *Ineligible study design*
 30. e Baere T. Another Brick in the Wall: Further Evidence Supporting the Efficacy of Thermal Ablation. *CardioVascular and Interventional Radiology*. 2020;43(12):1908-1909. *Ineligible study design*
 31. Ezer N, Mhango G, Wisnivesky JP. Radiofrequency ablation vs. conventional radiotherapy for unresected early stage non-small cell lung cancer. *American Journal of Respiratory and Critical Care Medicine*. 2014;189(MeetingAbstracts). *Ineligible publication type*
 32. Fanucchi O, Ambrogi MC, Dini P, Mussi A. Early stage NSCLC in high risk patients: Wedge resection VS radiofrequency ablation. *European Surgical Research*. 2010;45(3-4):247. *Unable to locate full text*
 33. Fanucchi O, Ambrogi MC, Melfi FMA, et al. Wedge resection vs. Radiofrequency ablation to treat early stage NSCLC in high-risk patients. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*. 2014;9(3):181. *Unable to locate full text*
 34. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: Preliminary results from the American College of Surgeons Oncology Group Z4032 Trial. *Journal of Thoracic and Cardiovascular Surgery*. 2011;142(3):554-562. *Ineligible intervention*
 35. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: Results from a multicenter phase III study. *Journal of Thoracic and Cardiovascular Surgery*. 2011;142(5):1143-1151. *Ineligible intervention*
 36. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. *Journal of Thoracic and Cardiovascular Surgery*. 2015;149(3):718-726. *Ineligible intervention*
 37. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: Results from ACOSOG Z4032 (alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. *Journal of Clinical Oncology*. 2014;32(23):2456-2462. *Ineligible intervention*
 38. Fernando HC, Santos RS, Benfield JR, et al. Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. *Journal of Thoracic and Cardiovascular Surgery*. 2005;129(2):261-267. *Ineligible intervention*
 39. Garnon J, Koch G, Rao P, et al. Optimising Pulmonary Microwave Ablation Using Trans-Scapular Access and Continuous Temperature Monitoring. *CardioVascular and Interventional Radiology*. 2016;39(5):791-794. *Ineligible publication type*
 40. Ghaye B. Percutaneous ablation of malignant thoracic tumors. *JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)*. 2013;96(3):142-54. *Ineligible study design*
 41. Grasso RF, Bernetti C, Pacella G, et al. A comparative analysis of thermal ablation techniques in the treatment of primary and secondary lung tumors: a single-center experience. *La Radiologia medica*. 2022;127(7):714-724. *Ineligible population*

42. Haasbeek CJA, Senan S, Smit EF, Lagerwaard FJ. CT-guided pulmonary radiofrequency ablation [8]. *Radiology*. 2008;246(1):334. *Ineligible study design*
43. Han HJ, Park SJ, Kim SR, et al. The comparison of effectiveness between surgical resection and radiofrequency ablation for stage I non-small cell lung cancer. *Respirology*. 2009;14(SUPPL. 3):A249. *Unable to locate full text*
44. Healey TT, Dupuy DE. Microwave ablation for lung cancer. *Medicine and health, Rhode Island*. 2012;95(2):52-3. *Ineligible publication type*
45. Healey TT, Dupuy DE. Microwave ablation for lung cancer. *Medicine and health, Rhode Island*. 2012;95(2):52-53. *Unable to locate full text*
46. Hiraki T, Gobara H, Mimura H, Sano Y, Kanazawa S. Percutaneous radiofrequency ablation of lung cancer. *The Lancet Oncology*. 2008;9(7):604-605. *Ineligible study design*
47. Jain SK, Simon CJ, Dupuy DE. Lung radiofrequency ablation. *Seminars in Interventional Radiology*. 2003;20(4):307-322. *Unable to locate full text*
48. Jang TW, Blackman G, George JJ. Survival benefits of lung cancer patients undergoing laser and brachytherapy. *Journal of Korean medical science*. 2002;17(3):341-347. *Ineligible population*
49. Jin GY, Lee JM, Lee YC, Han YM. Acute Cerebral Infarction after Radiofrequency Ablation of an Atypical Carcinoid Pulmonary Tumor. *American Journal of Roentgenology*. 2004;182(4):990-992. *Ineligible study design*
50. Jin GY, Lee JM, Lee YC, Han YM, Lim YS. Primary and secondary lung malignancies treated with percutaneous radiofrequency ablation: evaluation with follow-up helical CT. *AJR American journal of roentgenology*. 2004;183(4):1013-1020. *Ineligible population*
51. Kent MS, Mandrekar SJ, Landreneau R, et al. Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). *Annals of Thoracic Surgery*. 2016;102(1):230-238. *Ineligible outcome*
52. Kent MS, Mandrekar SJ, Landreneau R, et al. A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032). *Annals of Thoracic Surgery*. 2016;102(1):239-246. *Ineligible outcome*
53. Kido M, Kuruma H, Sasaki H, et al. Pulmonary metastases after low-dose-rate brachytherapy for localized prostate cancer. *Korean Journal of Urology*. 2014;55(5):309-314. *Ineligible population*
54. Kim EY, Kim YS, Kim JH. Thermal ablation for the treatment of primary and secondary pulmonary malignancies. *Journal of Thoracic Disease*. 2017;9(10):3641-3644. *Ineligible publication type*
55. Kishi R, Mimura H, Hiraki T, et al. Bleeding into a pulmonary cyst caused by pulmonary radiofrequency ablation. *Journal of vascular and interventional radiology : JVIR*. 2013;24(7):1069-71. *Ineligible study design*
56. Kotinsley KA, Betler J, Kotinsley B, et al. Outcome analysis of sublobar resection and intraoperative 125I brachytherapy vs. stereotactic body radiotherapy in stage I non-small cell lung carcinoma. *International Journal of Radiation Oncology Biology Physics*. 2011;81(2 SUPPL. 1):S162-S163. *Ineligible publication type*
57. Lam A, Yoshida EJ, Bui K, et al. Patient and Facility Demographics Related Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated with Radiofrequency Ablation: A National Cancer Database Analysis. *Journal of Vascular and Interventional Radiology*. 2018;29(11):1535-1541.e2. *Ineligible intervention*

58. Landreneau JP, Schuchert MJ, Abbas G, et al. Segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). *Journal of Surgical Research*. 2012;172(2):277-278. *Ineligible publication type*
59. Landreneau JP, Schuchert MJ, Weyant R, et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage i non-small cell lung cancer (NSCLC). *Surgery (United States)*. 2014;155(2):340-346. *Ineligible intervention*
60. Lau KKW, Waller DA, Rathinam S, Page R, Peake MD. Lung cancer resection rate is related to survival. *Thorax*. 2013;68(2):187. *Ineligible study design*
61. Lee H, Jin GY, Han YM, et al. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. *CardioVascular and Interventional Radiology*. 2012;35(2):343-350. *Ineligible population*
62. Li HW, Long YJ, Yan GW, et al. Microwave ablation vs. cryoablation for treatment of primary and metastatic pulmonary malignant tumors. *Molecular and Clinical Oncology*. 2022;16(3):62. *Ineligible population*
63. Li M, Qin Y, Mei A, Wang C, Fan L. Effectiveness of radiofrequency ablation therapy for patients with unresected Stage IA non-small cell lung cancer. *Journal of Cancer Research and Therapeutics*. 2020;16(5):1007-1013. *Ineligible intervention*
64. Li R, Ying Z, Yuan Y, et al. Comparison of two iodine-125 brachytherapy implant techniques for the treatment of lung tumor: Preplanning and intraoperative planning. *Brachytherapy*. 2019;18(1):87-94. *Ineligible intervention*
65. Li R, Zhang Y, Yuan Y, et al. Dosimetric comparison of CT-guided iodine-125 seed stereotactic brachytherapy and stereotactic body radiation therapy in the treatment of NSCLC. *PLoS ONE*. 2017;12(11):e0187390. *Ineligible outcome*
66. Louie AV, Senthil S, Palma DA. Surgery versus SABR for NSCLC. *The Lancet Oncology*. 2013;14(12):e491. *Ineligible study design*
67. Louie AV, Siva S, Senan S. Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer. *Cancer*. 2016;122(2):322-323. *Ineligible publication type*
68. Ma G-W, Pytel M, Trejos AL, et al. Robot-assisted thoracoscopic brachytherapy for lung cancer: comparison of the ZEUS robot, VATS, and manual seed implantation. *Computer aided surgery : official journal of the International Society for Computer Aided Surgery*. 2007;12(5):270-7. *Ineligible intervention*
69. Manning M, Sintay B, Wiant D, Ganem P, Moody JS. An overall survival comparison of sub-lobar resection with brachytherapy versus stereotactic body radiation therapy for early-stage non-small cell lung cancer. *International Journal of Radiation Oncology Biology Physics*. 2013;87(2 SUPPL. 1):S544. *Ineligible publication type*
70. Mantz CA, Dosoretz DE, Rubenstein JH, et al. Endobronchial brachytherapy and optimization of local disease control in medically inoperable non-small cell lung carcinoma: A matched-pair analysis. *Brachytherapy*. 2004;3(4):183-190. *Ineligible intervention*
71. Meade C, Quinn M, Pezzuti R, Dykes T, Gerding J. Predictors of tumor recurrence using positron emission tomography/computed tomography (PET/CT) after radiofrequency ablation of lung malignancies. *Journal of Vascular and Interventional Radiology*. 2010;21(12):1931. *Unable to locate full text*
72. Meng M, Huang G, Ye X, et al. Microwave ablation plus recombinant human endostatin (endostar) versus microwave ablation alone in inoperable stage I non small cell lung

- cancer. *Journal of Clinical Oncology*. 2018;36(15 Supplement 1). *Ineligible publication type*
73. Moghanaki D, Karas T. Surgery versus SABR for NSCLC. *The Lancet Oncology*. 2013;14(12):e490-e491. *Ineligible publication type*
74. Muto P, Ravo V, Panelli G, Liguori G, Fraioli G. High-dose rate brachytherapy of bronchial cancer: Treatment optimization using three schemes of therapy. *Oncologist*. 2000;5(3):209-214. *Ineligible population*
75. Narsule CK, Nair D, Gupta A, et al. Thermal ablation for stage IA non-small cell lung cancer: Long-term follow-up. *Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery*. 2014;9(3):181. *Unable to locate full text*
76. Narsule CK, Sridhar P, Nair D, et al. Percutaneous thermal ablation for stage IA non-small cell lung cancer: Long-term follow-up. *Journal of Thoracic Disease*. 2017;9(10):4039-4045. *Ineligible intervention*
77. Niemoeller OM, Pollinger B, Niyazi M, et al. Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors. *Radiation Oncology*. 2013;8(1):8. *Ineligible population*
78. Oesch A, Kuster R, Schmid RA. Limited resection or radiofrequency ablation for high risk patients. *Therapeutische Umschau*. 2012;69(7):429-432. *Ineligible language*
79. Parashar B, Arora S, Christos P, et al. Comparison of wedge resection versus wedge resection plus cesium-131 brachytherapy versus stereotactic body radiation therapy in management of early stage lung cancer patients that are not candidates for a standard lobectomy. *International Journal of Radiation Oncology Biology Physics*. 2013;87(2 SUPPL. 1):S203-S204. *Ineligible publication type*
80. Parashar B, Patel P, Monni S, et al. Limited resection followed by intraoperative seed implantation is comparable to stereotactic body radiotherapy for solitary lung cancer. *Cancer*. 2010;116(21):5047-5053. *Ineligible intervention*
81. Parashar B, Port J, Arora S, et al. Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer. *Brachytherapy*. 2015;14(5):648-654. *Ineligible intervention*
82. Patel M, Maraboyina S, Kim T. Brachytherapy vs External Beam Radiation in the Management of Non Small Cell Lung Cancer. *Brachytherapy*. 2019;18(3 Supplement):S39. *Ineligible publication type*
83. Patel MA, Fazli Y, Sivakumar S, et al. Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection. *Journal of Cancer Research and Clinical Oncology*. 2021;147(3):853-861. *Ineligible population*
84. Petera J, Neumanova R, Vrba M, et al. HDR intraluminal brachytherapy in the treatment of malignant bronchial obstructions. *Neoplasma*. 2000;47(1):56-9. *Ineligible population*
85. Platta S, Kruser TJ, Weigel TL, et al. Sublobar resection with intraoperative 125I brachytherapy vs stereotactic body radiation therapy for treatment of clinical early stage non-small cell lung cancer in patients not eligible for lobectomy. *Journal of Thoracic Oncology*. 2012;7(9 SUPPL. 4):S227-S228. *Ineligible publication type*
86. Potter R. Image-guided brachytherapy sets benchmarks in advanced radiotherapy. *Radiotherapy and Oncology*. 2009;91(2):141-146. *Ineligible publication type*
87. Pua BB, Thornton RH, Solomon SB. Radiofrequency Ablation: Treatment of Primary Lung Cancer. *Seminars in Roentgenology*. 2011;46(3):224-229. *Ineligible publication type*

88. Pusceddu C, Melis L, Fancellu A, Melis M, Meloni G. Feasibility and safety of percutaneous radiofrequency, microwave or cryoablation for unresectable thoracic malignancies in close proximity to heart and large vessels. *Annals of Surgical Oncology*. 2013;20(1 SUPPL. 1):S106. *Ineligible publication type*
89. Roy-Choudhury S. Lung alert. Inflammation caused by radiofrequency ablation for lung cancer is worse after radiotherapy and in large tumours. *Thorax*. 2008;63(11):998. *Ineligible study design*
90. Safi S, Op Den Winkel J, Rauch G, et al. Outcomes following sublobar resection, radiofrequency ablation or radiotherapy for stage I non-small-cell lung cancer: A retrospective analysis. *Interactive Cardiovascular and Thoracic Surgery*. 2014;18(SUPPL. 1):S17. *Ineligible publication type*
91. Sainani NI, Shyn PB, Tatli S, Morrison PR, Tuncali K, Silverman SG. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation? *Journal of vascular and interventional radiology : JVIR*. 2011;22(3):354-60. *Ineligible population*
92. Santos R, Colonias A, Parda D, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. *Surgery*. 2003;134(4):691-697. *Ineligible intervention*
93. Scappaticci AA, Yoo DC. Recurrence of lung cancer after radiofrequency ablation detected by PET/CT and contrast enhanced CT scan. *Medicine and health, Rhode Island*. 2012;95(5):146-148. *Ineligible study design*
94. Schneider T, Reuss D, Warth A, et al. The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. *European Journal of Cardio-thoracic Surgery*. 2011;39(6):968-973. *Ineligible population*
95. Seibold P, Webb A, Aguado-Barrera ME, et al. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. *Radiotherapy and Oncology*. 2019;138:59-67. *Ineligible population*
96. Sharma DN, Rath GK. Brachytherapy for medically inoperable lung cancer. *The Lancet Oncology*. 2009;10(12):1141-2. *Ineligible study design*
97. Shi F, Li G, Zhou Z, et al. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. *Oncotarget*. 2017;8(65):109791-109798. *Ineligible population*
98. Shyn PB. Is image-guided thermal ablation ready for treatment of stage 1 non-small cell lung cancer? *Radiology*. 2018;289(3):871-872. *Ineligible publication type*
99. Skonieczki BD, Wells C, Wasser EJ, Dupuy DE. Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: Is it safe? *European Journal of Radiology*. 2011;79(3):343-346. *Ineligible population*
100. Skowronek J. Lung cancer brachytherapy. *International Journal of Cancer Research and Prevention*. 2011;4(2):97-126. *Ineligible study design*
101. Smith S, Jennings P. Thoracic intervention and surgery to cure lung cancer: image-guided thermal ablation in primary lung cancer. *Journal of the Royal Society of Medicine*. 2019;112(6):218-225. *Ineligible study design*
102. Sofocleous CT, Sideras P, Petre EN, Solomon SB. Ablation for the management of pulmonary malignancies. *American Journal of Roentgenology*. 2011;197(4):W581-W589. *Ineligible study design*
103. Steinke K, Liu H. Minimally invasive techniques for medically inoperable stage i non-small cell lung cancer (NSCLC) - Image-guided microwave ablation, a promising therapy

- option. *Journal of Medical Imaging and Radiation Oncology*. 2014;58(1):79-80. *Ineligible publication type*
104. Tam TY, Rosenzweig KE, Rimner A, et al. Chronic obstructive pulmonary disease predicts for increased respiratory toxicity in patients with early-stage non-small cell lung cancer treated with stereotactic body radiotherapy. *International Journal of Radiation Oncology Biology Physics*. 2011;81(2 SUPPL. 1):S591. *Ineligible publication type*
105. Tselikas L, Garzelli L, Mercier O, et al. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. *Diagnostic and Interventional Imaging*. 2021;102(1):19-26. *Ineligible population*
106. Venturini M, Cariati M, Marra P, Masala S, Pereira PL, Carrafiello G. CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours. *CardioVascular and Interventional Radiology*. 2020;43(5):667-683. *Ineligible study design*
107. Versteegen NE, Oosterhuis JWA, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2013;24(6):1543-8. *Ineligible population*
108. Vogl TJ, Basten LM, Nour-Eldin NEA, Kaltenbach B, Ackermann H, Naguib NNN. Microwave ablation (MWA) of pulmonary neoplasms: Clinical performance of high-frequency MWA with spatial energy control versus conventional low-frequency MWA. *American Journal of Roentgenology*. 2019;213(6):1388-1396. *Ineligible population*
109. Vogl TJ, Roman A, Nour-Eldin NEA, Hohenforst-Schmidt W, Bednarova I, Kaltenbach B. A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases. *Diagnostic and Interventional Radiology*. 2018;24(1):31-37. *Ineligible population*
110. Voynov G, Heron DE, Lin CJ, et al. Intraoperative 125I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I nonsmall cell lung cancer. *Brachytherapy*. 2005;4(4):278-285. *Ineligible intervention*
111. Zaric B, Canak V, Milovancev A, et al. The effect of Nd:YAG laser resection on symptom control, time to progression and survival in lung cancer patients. *Journal of BUON*. 2007;12(3):361-368. *Ineligible intervention*
112. Zhang Z, Mao H, Wang X, Sheng W. Comparison of I125seed brachytherapy (radioactive seed brachytherapy) joint three-dimensional conformal radiotherapy and stereotactic ablative radiotherapy on early nonsmall cell lung cancer. *Journal of Cancer Research and Therapeutics*. 2020;16(7):1560-1568. *Ineligible population*

APPENDIX C. RISK OF BIAS RATINGS (KQ1 ONLY)

Publication	Trial	Domain 1: Risk of Bias Arising from the Randomization Process	Domain 2a: Risk of Bias Due to Deviations from the Intended Interventions (Effect of Assignment to Intervention)	Domain 2b: Risk of Bias Due to Deviations from the Intended Interventions (Effect of Adherence to Intervention)	Domain 3: Risk of Bias Due to Missing Outcome Data	Domain 4: Risk of Bias in Measurement of the Outcome	Domain 5: Risk of Bias in Selection of the Reported Result	Overall Risk of Bias
Chang, 2015 ¹³	STARS NCT00840749	Low	Low	Low	Low	Low	Some concerns	Some concerns
	ROSEL NCT00687986	Low	Low	Low	Low	Low		
Louie, 2015 ¹⁴	ROSEL NCT00687986	Low	Low	Low	Low	Some concerns	Low	Some concerns

Abbreviations. ROSEL=Trials of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer; STARS=Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer.

APPENDIX D. PEER REVIEW DISPOSITION

Comment #	Reviewer #	Comment	Author Response
<i>Are the objectives, scope, and methods for this review clearly described?</i>			
1	1	Yes	Thank you.
2	2	Yes	Thank you.
3	4	Yes	Thank you.
4	5	Yes	Thank you.
5	6	Yes	Thank you.
6	8	No - See my comments below	Thank you.
<i>Is there any indication of bias in our synthesis of the evidence?</i>			
7	1	No	Thank you.
8	2	No	Thank you.
9	4	No	Thank you.
10	5	No	Thank you.
11	6	No	Thank you.
12	8	No	Thank you.
<i>Are there any published or unpublished studies that we may have overlooked?</i>			
13	1	No	Thank you.
14	2	No	Thank you.
15	4	No	Thank you.
16	5	Yes - Lencioni et al. Lancet Oncol 2008; 9:621-628. Palussiere et al. J Cardiovasc Surg 2018; 13:91	Thanks for pointing these out. Both studies were captured by our search but excluded during title and abstract screening process since these were single arm studies without a comparison group.
17	6	No	Thank you.
18	8	No	Thank you.
<i>Additional suggestions or comments can be provided below.</i>			
	1	ES Key Findings; second bullet:	We revised per suggestion.

Comment #	Reviewer #	Comment	Author Response
		I'd use "patient-centered" language throughout. Suggest here " for patients with medically" Suggest changing throughout	
	1	ES Key Findings; fourth bullet: Not sure why you have this recommendation here, it's not a finding. If you have a recommendation for KQ1-2, why not KQ3?	The bullet refers to the findings from our evidence map and notes that cryoablation, radiofrequency ablation, microwave ablation and laser ablation were studied. We then provide "sub-bullet items" directly below to note the volume of literature and the comparisons identified. This is consistent with evidence map summaries. No change.
	1	ES Key Findings; last bullet: Fine to leave in but I don't understand why lung cancer screening is relevant here.	We left unchanged. We believe this last bullet is important for our VA partners to understand the applicability of current research for Veterans. Additionally, all the studies were conducted prior to widespread lung cancer screening. Screening alters characteristics of disease detected (eg, smaller and potentially less lethal cancers) and the characteristics of patients who are referred and found to have possible lung cancer. This is particularly important when discussing the potential role of treatments other than surgery as current USPSTF guidelines recommend lung cancer screening only for individuals considered candidates for surgery or willing to undergo surgery.
	1	ES Intro; page 10 line15 " medically inoperable": I might clarify this term. "patient's with comorbidities that place them at high-risk for severe complications during or after surgical resection for lung cancer"	Added: "(due to advanced age or with comorbidities that place them at high-risk for severe perioperative complications)."
	1	ES: Maybe this is just how you write all Summaries. But it seemed a little weird to read the whole thing and never have the KQ's spelled out.	Thanks for bringing this to our attention, the KQs have been added to our Executive Summary.
	1	ES Intro, page 10 line 26: Above you said "early", here "Stage I". I suggest being consistent and/or clarifying the difference.	Thank you for noting this. We have clarified use of the term "stage 1" when specifically addressing the studies and the key question (the population of interest is "adults with medically operable stage 1 non-small cell lung cancer." However, in the introduction and discussion we use the broader term "early stage", for example, we note

Comment #	Reviewer #	Comment	Author Response
			that the evaluated strategies are used for an expanded group defined as those with “early-stage lung cancer”.
1		ES Future Research last bullet: This last bullet point and the sentence that begins, "Finally, studies..." seem outside the scope of the Systematic Review. A minor style point is why is the "Finally, studies..." sentence not w/ the bullets?	Thank you. We have added bullets to last two research items. An important part of the future research needs paragraph is to identify and highlight the identified gaps in current research in the context of our systematic review. We have left this sentence unchanged.
1		Methods, KQ page 16 line 40: Maybe not here but do you want to explain why KQ 1-2 only included RCTs and why KQ3 was any comparative study? Why didn't you include non-RCT comparative studies in KQ1-2 or have an additional question? There might already be systematic reviews of the observational studies that would have been in KQ1-2 that you might want to cite.	Thank you. We have added rationale for our inclusion criteria and outlined the limitations of observational studies in addressing this question. We did reference one of the existing systematic reviews but did not perform a comprehensive review of reviews.
1		Table 3 tumor stage: You might want to add a footnote for which AJCC version they used for stage	This has been added.
1		Figure 4: Don't you still need a reference? Is a big bubble 10 people and a small one 1?	Thanks for pointing this out, more explanation was added to the figure to describe absolute sample size.
2		The following editorial recommendations are indicated by the PDF page # P6 line 52 – I recently resigned as NODES co-director. Please changes title to: Drew Moghanaki, MD, MPH Staff Physician Co-Director Lung Precision Oncology Program VA Greater Los Angeles Healthcare System	This has been updated.
2		P12 line 38 – consider clarifying these are “retrospective comparative studies”	This has been clarified.

Comment #	Reviewer #	Comment	Author Response
2		P13 line 30 – consider adding (NCT02984761) after “SBRT”.	Thank you, the NCT# has been included.
2		Methods – it would help readers to define the KQs earlier in the manuscript, perhaps in the first paragraph?	Thank you. The KQs have been added to our Executive Summary.
2		P13 line 49 – it’s unclear what “dual consensus” is. Consider clarifying.	Changed to read: Any article judged to be excluded at the abstract level required confirmation by a second reviewer; articles included by either reviewer was advanced to the full-text review stage.
2		P13 line 51 – the manuscript hasn’t clarified yet who comprises the group that is resolving disagreements by consensus	Consensus included all named ESP review authors as issues of disagreement included research methods and clinical content and therefore required discussion with the broader group.
2		P13 line 53 – it’s difficult to follow the last two sentence in this paragraph since KQs aren’t yet defined at this point	Thanks for bringing this to our attention, the KQs have been added to our Executive Summary, which should help the reader.
2		P14 line 60 – the study team isn’t defined yet	Changed to read “systematic review authors”.
2		P15 line 25 – I was hoping for a conclusion of the KQ3 summary as stated for KQ1	Our conclusion from the evidence maps includes a description of the quantity and breadth of evidence for specific questions. Because the heterogeneity of the studies with respect to patient populations, interventions, and study designs, we did not pool across studies and make inferences about effect size or overall certainty of evidence.
2		P15 line 43 – I would use the term “safety” instead of “harms”	Thank you but this has been left unchanged. Harms is standard term when referring to “complications”/adverse effects of an intervention.
2		P15 line 54 – “are unlikely”	This has been corrected.
2		P16 line 12 – instead of 17, please state “at least 16”	This has been corrected.
2		P16 line 16 – the vast majority of stage I NSCLC will continue to be diagnosed incidentally, with the minority being screen-detected. Therefore, it may be better to rephrase this sentence to “Individuals eligible for VALOR and other future comparative effectiveness studies are more likely to have lung cancers detected by lung cancer screening than in previous publications.”	Thank you. We have removed this sentence.

Comment #	Reviewer #	Comment	Author Response
2		P16 line 26 – consider “randomized trial data” instead of “randomized trials”	Thank you. This has been changed.
2		P17 line 14 – consider “treatment outcome uncertainty”	This has been changed.
2		P23 line 34 – clarify “randomized trials”	This has been addressed.
2		P23 line 44 – this sentence is difficult to reconcile (is it higher rates of relapse?)	We agree this is confusing. We reviewed this and believe it is most appropriate to note the difference in the follow-up intervals and not speculate on the possibility for undetected relapses.
2		P41 line 44 – replace “17” with “at least 16”	This has been corrected.
4		<p>The VA Evidence Synthesis Program review of the state of evidence about Non-Surgical Therapies for Early-Stage Non-Small Cell Lung Cancer by Shahnaz Sultan and colleagues describes the current state of evidence for SABR and for other ablative therapies for NSCLC. Overall, the manuscript is very well-written and describes very well the current state of the evidence base for the 3 Key Questions.</p> <p>For KQ 1, they reference only the RCTs which were ended early with very low numbers because of poor accrual. This is quite poor evidence for decision-making and thus describes a situation where more well-designed studies and more evidence is needed.</p> <p>For KQ 2, there was not enough good evidence found to inform any answers at all.</p> <p>For KQ 3, 18 retrospective studies were referenced, including many different comparison arms, but no solid conclusions could be made from any of those studies. I found it unusual that they used non-randomized, retrospective studies for the ablative therapies question (KQ 3) but did not consider any of the non-randomized data for KQ 1 and 2. For those questions KQ 1 and 2, there are innumerable studies in the medical literature using non-randomized data, many which show improved outcomes with surgery as compared to SABR, and I would think some commentary on that data would be warranted.</p> <p>Also, I would have liked to see some sort of conclusion statement for KQ 3, based on the data reviewed, even if</p>	<p>Thank you for the comments. We added information to justify our different criteria for KQ1 and 2 vs. KQ3. Essentially, in consultation with our Nominating Partner and TEP members we focused on evidence from randomized controlled trials to address comparative effectiveness and harms of surgery vs. radiation therapy for Stage 1 non-small cell lung cancer in medically operable adults. This decision was based on evidence that current data from nonrandomized trials were inadequate to adequately inform clinical and policy decisions.</p> <p>The goal of KQ3 was subsequently refined from the original topic nomination brief to include an evidence map of all “alternative” ablative therapies used as monotherapy to treat stage I lung cancer. With an evidence map, we intentionally broadened our scope to include comparative studies that were RCTs as well as non-RCTs since the focus of an evidence map is to provide an overview of the breadth of the evidence of all comparative studies across a range of ablative therapies and outcomes reported. We did not formally rate study risk of bias, extract effect sizes or assess overall certainty of evidence. We agree that the evidence is likely very limited for “alternative ablative therapies”. There is not sufficient evidence for us to directly compare SABR with “alternative ablative therapies</p>

Comment #	Reviewer #	Comment	Author Response
		<p>it is the most minimal of conclusions that are able to be drawn. I say this because I find the evidence for those alternative ablative therapies to be much less strong than for SABR. I would like to see some summary conclusions stating that the outcomes are superior with SABR as well as with surgery when these retrospective comparisons are made if the authors are able to do so. I do believe that the RCT comparison of SABR to surgery is a very worthwhile pursuit, whereas those other ablative therapies do not have as much promise and do not warrant large RCTs in operable patients. And I do not think most surgeons who treat lung cancer would have equipoise for such an RCT. But I can understand that the authors did not feel the evidence warranted much in the way of conclusions.</p> <p>Overall, I think the authors did a tremendous job of describing the current state of the literature on these topics. But the current state leaves many unanswered questions and thus points to further research needs.</p>	<p>We have further highlighted the limited quality (based on study design (mostly administrative data sets); country of origin, interventions and comparisons and outcomes of interest.). Such reporting can highlight gaps in research evidence.</p> <p>We thank the reviewer for the statement of our overall work. We agree that the current evidence has many gaps and requires future research. We agree that RCT are needed (especially in screen detected lung cancer) and provide this as recommended future research. We summarize some suggested future research to close those gaps.</p>
5		<p>Although I believe the conclusions of the report are accurate, it discounts so much data because of the narrowness of the criteria to answer the questions, making most studies ineligible. With few randomized trials to include, it is expected that this report has little to ultimately conclude, most of which was obvious. As such, this report feels a bit hollow; in that, there is no information of the current status, benefits, outcomes and usefulness of any ablation modality, for instance, despite 3 trials, database studies, etc. to be useful. If the VA waits for or conducts a randomized trial, that would be great, but what therapies can be offered until this occurs - this report sheds no light. If a trial is to be conducted, it should have 3 arms with thermal ablation included, so that we can understand where and how each modality (surgery, SBRT, ablation) fits into the treatment paradigm and which patient and which tumor location would be appropriate for each of the local therapies.</p>	<p>We appreciate the concerns of this reviewer. Based on discussion with our Nominating Partner and TEP members the viewpoint was that a review that included information from non-RCT would not adequately inform clinical practice and policy and that prior reviews had not resolved that issue. Excluding a large body of data is justified because it is likely to be biased and provide inaccurate information that could wrongly guide clinical decisions and impede needed research. Thus, one is left with very little data to guide clinical decision making...that in and of itself can be viewed as a very important "take home message" including the importance of completing RCTs that address the issue.</p> <p>We thank the reviewer for the suggestion on a three-arm trial. We have included this in our future research need.</p>
6		<p>Thank you for the opportunity to evaluate this report.</p>	<p>This has been corrected for consistency.</p>

Comment #	Reviewer #	Comment	Author Response
		As a small typo the wording of KQ2 is different on pages 16 and 20	
6		<p>Overall, there are three significant limitations.</p> <p>1. It is not clear why KQ1 and KQ2 were limited to RCTs but KQ3 was not. There are certainly biases present when comparing ablative therapies to either surgery or radiation, so the question arises of why include observational studies with KQ3 but not the other two key questions. There have been attempts with retrospective cohorts to compare SBRT and surgery, why not include the data from these studies with the caveats that go along with these types of investigations and the discussion of the associated risks of bias and certainty of evidence. The shortcomings of retrospective studies would emphasize the need for RCTs in this space but provide the best evidence we currently have.</p>	Please see our points discuss above.
6		<p>2. As I interpret KQ2 (on page 16) wouldn't the prospective studies limited to either SBRT or surgery for early-stage NSCLC address this question. For example, a RCT of SBRT vs surgery is not needed to address the benefits and harms of "surgery characteristics (type of surgery [minimally invasive vs. open])" or "SBRT characteristics (eg, dose, fractionation)". It is likely that any SBRT vs surgery RCT will be underpowered to address these questions anyway. Along these lines, the VALOR study does not allow for single fraction SBRT, but there are studies RCT of single fraction SBRT that address this topic. A thoughtful analysis of the benefits and harms elucidated by trials of either modality may indicate those patients which may be better served by an alternate approach and set the stage for prospective studies.</p>	We thank the reviewer for this comment. KQ2 specifically focuses on whether the effectiveness and harms of SBRT or surgery vary by these characteristics, essentially subgroup findings or effect modification. Use of non-RCTs would be limited in a similar fashion for KQ2 as for KQ1
6		<p>3. The "quantity and characteristics" of studies addressing ablative techniques are well summarized in the results of KQ3 but it is unclear why this KQ was limited to this "meta" question. Reading through the manuscript I expected a full discussion of the findings of these studies, again with discussion of the caveats of the</p>	We thank the reviewer for this. As noted previously the intent of KQ3 was to provide an evidence map summarizing the state of the literature according to intervention/comparison, study type and outcomes reported rather than effect size estimates or directionality. As with KQ1 and 2 the current evidence base for KQ3

Comment #	Reviewer #	Comment	Author Response
		<p>observational studies that I presume were included.</p> <p>In summary, this ESP report provides an in-depth evaluation of one, underpowered analysis of two prematurely terminated RCTs. Serious thought should be given to expanding KQ1 to include observational studies, KQ2 to include prospective studies addressing SBRT or surgery individually, and a complete discussion of the results of studies identified for KQ3.</p>	<p>would necessarily be very limited in number and poor in quality as almost all reports were observational and frequently from administrative data (sometimes using overlapping data systems).</p> <p>Our ESP review team worked in consultation with our Nominating Partner and TEP members to determine study inclusion criteria. As noted previously, inclusion of findings from nonrandomized trials was deemed inadequate to accurately inform clinical decision making and could impede future RCTs if the perception was that non-RCT could sufficiently address. We did highlight one non-RCT in the discussion section and note the serious methodologic limitations in this widely cited report and thus the inability of non-RCTs to adequately resolve treatment uncertainty.</p>
8		<p>Thank you for the opportunity to review this manuscript. The authors have assembled the data available for assessing the use of ablative therapies for early-stage non-small cell lung cancer. The manuscript is well written and the data clearly presented. However, I think there a few aspects that could improve the evidence synthesis. These points are detailed below.</p> <p>1. The Key questions missing from the executive summary and do not appear in the manuscript until page 16 (19 in the pdf) although they are mentioned throughout the executive summary. I would recommend adding the key questions to the key findings box.</p>	<p>Thanks for bringing this to our attention, the KQs have been added to our Executive Summary.</p>
8		<p>2. Table 3. Data in the STARS trial is listed in the table as NR, although was apparently available to the authors of the Chang publication (#13 in the references). It would be helpful to the reader if that missing STARS data was extracted from the Chang publication and then footnoted regarding the way it was determined (not from the primary investigators, but via the Change publication). This would make it easier for the reader to compare the populations of the STARS and ROSEL trials directly.</p>	<p>Thank you for the suggestion, however, the Chang publication did not report results separately by trial, so this information was not available to review authors.</p> <p>Review authors did attempt to contact the trial investigators of the STARS study for this data but were unsuccessful.</p>

Comment #	Reviewer #	Comment	Author Response
8		3. Table 5. The SABR and Surgery columns are reversed	Thank you for bringing this to our attention, this has been corrected.
8		4. I wonder if the decision to use evidence mapping for key question 3 was the right one. As someone who may be interested in seeking out an evidence synthesis like the one presented here, I would be most interested in seeing what the outcomes of the accumulated data was. I recognize the limitations associated with the retrospective and/or observational data presented in the selected publications, as well as the value of the summary data that was presented. Nevertheless, I think a brief summary of the outcomes, perhaps limited to just the studies from the larger database publications, and with the appropriate qualifications around how to interpret this data, would be very valuable. Alternatively, if the authors feel strongly about not including outcome data from the studies for key question 3 there should be a statement in the methods section for key question 3 similar to this statement from the limitations section: “we also did not provide information on effect size, direction of effect, or assessment of quality of studies to limit misinterpretation or over reliance of these studies for decision-making”, to alert the reader to the limited nature of the evidence mapping.	Thank you. We note previously our rationale for conducting an evidence map.